

1 A. Marisa Chun (SBN 160351)
mchun@crowell.com
2 Kristin J. Madigan (SBN 233436)
kmadigan@crowell.com
3 Suzanne E. Rode (SBN 253830)
srode@crowell.com
4 CROWELL & MORING LLP
3 Embarcadero Center, 26th Floor
5 San Francisco, California 94111
Telephone: 415.986.2800
6 Facsimile: 415.986.2827

7 Norman J. Hamill (SBN 154272)
norman.hamill@ucop.edu
8 Katharine Essick (SBN 219426)
katharine.essick@ucop.edu
9 UNIVERSITY OF CALIFORNIA
Office of General Counsel
10 1111 Franklin Street, 8th Floor
Oakland, CA 94607-5200
11 Telephone: 510.987.9800
Facsimile: 510.987.9757

12 *Attorneys for Defendants*
13 The Regents of the University of California and
Michael V. Drake
14

15 SUPERIOR COURT OF THE STATE OF CALIFORNIA

16 COUNTY OF ALAMEDA

17 CINDY KIEL, J.D., an Executive Associate
Vice Chancellor at UC Davis, MCKENNA
18 HENDRICKS, a UC Santa Barbara student,
EDGAR DE GRACIA, a UCLA student, and
19 LELAND VANDERPOEL, an employee at the
Fresno satellite extension of the UCSF Medical
20 Education Program, and FRANCES OLSEN,
Professor of Law at UCLA,

21 Plaintiff,

22 v.

23 THE REGENTS OF THE UNIVERSITY OF
24 CALIFORNIA, a Corporation, and MICHAEL
V. DRAKE, in his official capacity as President
25 of the UNIVERSITY OF CALIFORNIA,

26 Defendants.
27
28

Case No. HG20072843

Unlimited Civil Jurisdiction

ASSIGNED FOR ALL PURPOSES TO:
Hon. Richard L. Seabolt
Department 521

**DECLARATION OF DR. ARTHUR L.
REINGOLD, M.D. IN SUPPORT OF
DEFENDANTS' OPPOSITION TO
PLAINTIFFS' MOTION FOR
PRELIMINARY INJUNCTION**

Date: October 14, 2020
Time: 01:30 p.m.
Dept.: 521
Reservation No.: 2206283

Complaint filed: August 27, 2020
Trial: None set

1 I, Arthur L. Reingold, M.D., declare:

2 1. I provide this declaration in support of Defendants The Regents of the University
3 of California and Michael V. Drake's ("Defendants") Opposition to Plaintiffs' Motion for
4 Preliminary Injunction. I base this declaration on my expertise as outlined below and facts within
5 my personal knowledge, to which I could and would testify competently if called upon to do so.

6 2. I am the Division Head of Epidemiology at the University of California, Berkeley,
7 School of Public Health. I have worked on the prevention and control of infectious diseases in
8 both the United States, including eight years at the U.S. Centers for Disease Control and
9 Prevention ("CDC"), and with numerous developing countries around the world for over forty
10 years. Since its inception in 1994, I have directed or co-directed the CDC-funded California
11 Emerging Infections Program. I am a member of the Society for Epidemiologic Research and the
12 American Epidemiological Society; an elected Fellow of the Infectious Disease Society of
13 America and of the American Association for the Advancement of Science; and an elected
14 member of the Institute of Medicine of the National Academy of Sciences. I was previously the
15 President of both the Society for Epidemiologic Research and the American Epidemiological
16 Society. I have served on the editorial boards of the following journals: American Journal of
17 Epidemiology, Epidemiology, and Global Public Health. I am also currently an Associate Editor
18 of the journal, Vaccine.

19 3. I received my A.B. in biology from the University of Chicago in 1970, and my
20 M.D. from the University of Chicago in 1976. Among other things, I completed a residency in
21 internal medicine and a preventive medicine residency with the CDC.

22 4. My career in public health has been in the area of infectious diseases and
23 epidemiology. Following my positions at the CDC (1979–1987), I joined the faculty of the
24 School of Public Health at Berkeley as a Professor of Epidemiology (1987–present), the faculty
25 of the Department of Epidemiology and Biostatistics at the University of California, San
26 Francisco ("UCSF") (1989–present), and as a Clinical Professor in the Department of Medicine at
27 UCSF (1991–present). From 1990–1994, I was the Head of the Epidemiology Program,
28 Department of Biomedical and Environmental Health Sciences, University of California,

1 Berkeley; from 1994–2000, I was the Head of the Division of Public Health Biology and
2 Epidemiology, University of California, Berkeley. Since 2000, I have been Head of the Division
3 of Epidemiology, School of Public Health, University of California, Berkeley.

4 5. My research focuses on emerging and re-emerging infections in the United States
5 and in developing countries; respiratory infections and vaccine-preventable diseases in the United
6 States and in developing countries, including influenza and, since it emerged in 2020, COVID-19;
7 and disease surveillance, outbreak detection, and outbreak response.

8 6. Attached hereto as Exhibit A and incorporated by reference to this declaration is a
9 copy of my curriculum vitae.

10 ***Background on COVID-19***

11 7. I am currently involved in multiple projects related to SARS-CoV-2, a novel
12 coronavirus that causes Coronavirus Disease 2019 (COVID-19). I am collaborating on research
13 concerning SARS-CoV-2 and its incidence, and serving on SARS-CoV-2 advisory groups for
14 multiple organizations, including UC Berkeley, the University of California system, and the City
15 and County of San Francisco, among others. I have recently served on two COVID-related
16 committees for the National Academy of Science, Engineering, and Medicine: I helped organize
17 and moderate a two-day workshop on the Role of Aerosols in Transmitting SARS-CoV-2, and I
18 worked as a member of the committee on the Equitable Distribution of COVID-19 Vaccines in
19 the U.S.

20 8. As of September 27, 2020, there were over 7.1 million confirmed cases of
21 COVID-19 in the United States, and over 204,000 confirmed deaths caused by the virus.¹
22 Nationally, the number of confirmed cases has increased dramatically since the pandemic began
23 in early 2020. In California alone, there are approximately 800,000 confirmed cases and over
24 15,000 deaths.²

25 9. Importantly, the rise in cases is not just a reflection of increased testing. If the rate
26 of COVID-19 were stable or decreasing, increased testing would produce a lower proportion of

27 ¹ Johns Hopkins, “Coronavirus Resource Center,” available at <https://coronavirus.jhu.edu/us-map>
28 (last accessed Sept. 25, 2020).

² *Id.* at <https://coronavirus.jhu.edu/region/us/california> (last accessed Sept. 25, 2020).

1 tests being positive, as presumably, a larger and more representative selection of the population
2 (not only those with symptoms or known exposure) would be included. Since the case rate and
3 the proportion of tests positive rate have increased simultaneously, data suggest that the increase
4 in confirmed cases indicates a true rise in cases, as do the numbers and rates of COVID-19
5 hospitalizations and deaths.³

6 10. SARS-CoV-2 virus is a respiratory virus; COVID-19 patients typically, but not
7 invariably, present with acute respiratory signs and symptoms. The most common symptoms are
8 fever, cough, and shortness of breath. Other identified symptoms include muscle aches,
9 headaches, chest pain, diarrhea, coughing up blood, sputum production, runny nose, nausea,
10 vomiting, sore throat, confusion, loss of senses of taste and smell, and loss of appetite. Due to the
11 respiratory impacts of the disease, individuals may need to be put on oxygen, and in severe cases,
12 patients may need to be intubated and put on a ventilator. COVID-19 can lead to respiratory
13 failure, other organ failure, and/or other serious, life-threatening complications, such as
14 cardiovascular events, strokes, and seizures. Strokes have been reported in people in their thirties.
15 COVID-19 cases in children, while less frequent, can be severe, even fatal. COVID-19 is also
16 known to impact the brain and nervous system.

17 11. Pandemics like the current one occur when the number of infections grows
18 exponentially. Fixed rate exponential growth means that the number of infections doubles in a
19 defined amount of time. For example, if on day one of the outbreak there are 100 infected
20 individuals and the doubling period is five days, by day six (five days later) 200 individuals will
21 have become infected, and by day 11 (five days later) 400 individuals will have become infected.
22 By contrast, linear growth would mean a steady increase in infections per a given period of time
23 (e.g., 100 new infections every five days). The shorter the doubling time, the greater the growth
24 rate of the epidemic/pandemic. If exponential growth rates are not moderated, the number of
25 infections and resultant illnesses can quickly overwhelm a given health system. The term
26 “flattening the curve” refers to attempts to lengthen the doubling period of infections and thereby

27 ³ New York Times, “Covid in the U.S.: Latest Map and Case Count,” available at
28 <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html> (last accessed Sept. 27, 2020).

1 prevent a collapse of the healthcare system. Reducing the growth rate of infections and resultant
2 disease is achieved through both official policies and changes to individual social behavior.

3 12. Many models indicate that SARS-CoV-2 infections and cases of COVID-19 will
4 persist through the end of 2020 and into 2021.⁴ Their persistence (and indeed surge) during the
5 summer months only underscores the likelihood that SARS-CoV-2 and COVID-19 cases will be
6 present in the U.S. throughout the time period coinciding with the upcoming influenza season.
7 Currently, there is no cure for COVID-19 nor any foolproof means of preventing its spread, short
8 of complete isolation.

9 13. There is not yet an FDA-approved vaccine against SARS-CoV-2 that could be
10 used to immunize the population against the virus. Most experts do not expect widespread
11 availability of a COVID-19 vaccine until 2021, at the earliest. Dr. Fauci of the National Institutes
12 of Health (NIH) has recently stated that it is possible a vaccine may be ready as early as the end
13 of 2020. However, it would take significantly more time before substantial numbers of doses of
14 the vaccine become readily available and can be delivered to the public at large. In no currently
15 foreseeable circumstances is an effective vaccine anticipated to be broadly distributed before the
16 upcoming influenza season in the U.S.

17 14. Due to the ease of transmission, the high risk to certain parts of the population, and
18 the fact that SARS-CoV-2 will continue to spread unless and until widespread vaccination and/or
19 herd immunity is achieved, individuals will need to continue to take steps to prevent infection and
20 reduce the burden on healthcare delivery systems.

21 *Safety and Efficacy of Influenza Vaccine*

22 15. There are reasons to believe that the continued COVID-19 pandemic may have an
23 even more severe impact during the fall of 2020 and winter of 2020-2021 because of the

24 ⁴ Kristine A. Moore, Marc Lipsitch et al., "COVID-19: The CIDRAP Viewpoint," CIDRAP
25 (April 30, 2020): [https://www.cidrap.umn.edu/sites/default/files/public/downloads/cidrap-](https://www.cidrap.umn.edu/sites/default/files/public/downloads/cidrap-covid19-viewpoint-part1_0.pdf)
26 [covid19-viewpoint-part1_0.pdf](https://www.cidrap.umn.edu/sites/default/files/public/downloads/cidrap-covid19-viewpoint-part1_0.pdf) (concluding based on lessons from previous influenza pandemics
27 that in a best case scenario, COVID-19 would continue for 18 months, which from time of
28 publication would be October 2021); Ryan Best and Jay Boice, "Where The Latest COVID-19
Models Think We're Headed -- And Why They Disagree," FiveThirtyEight (August 6, 2020):
<https://projects.fivethirtyeight.com/covid-forecasts/> (comparing 15 models published by scientists
to illustrate possible trajectories of the pandemic's death toll, all of which show increases in
COVID-19 deaths through at least September 2020).

1 overlapping effects of influenza (flu). Influenza is a respiratory virus that peaks seasonally in the
2 fall and winter, and produces many of the same symptoms as COVID-19. The COVID-19
3 pandemic arrived in the U.S. as the 2019-2020 influenza season was coming to an end. As a
4 result, no region of the U.S. has yet experienced co-circulation of the SARS-CoV-2 virus and
5 various influenza viruses, so there is no evidence one way or another concerning what might
6 happen if an individual were to become infected with both viruses at the same time. However,
7 both influenza and SARS-CoV-2 cause severe, life-threatening infections of the respiratory tract
8 and related complications, hospitalizations, intensive care unit admissions, need for intubation,
9 and death, and both of them are particularly severe in the elderly and those with various
10 underlying medical conditions. As colder weather forces more people to be indoors and with both
11 viruses expecting to be in widespread circulation in the U.S. this winter, it is highly likely that the
12 dual impact on hospitals and the healthcare system in general will be substantial, quite possibly
13 exceeding the impact of either disease alone, and in the absence of a widely available effective
14 and safe COVID-19 vaccine, influenza vaccine and vaccination will be a very important tool for
15 minimizing the burden on the healthcare system and also minimizing illnesses, hospitalizations,
16 and deaths due to respiratory infections. Moreover, if all these viral infections occur at the same
17 time, it will be more difficult to determine whether symptoms are indicative of COVID-19 or
18 influenza virus infection in individual patients and the population more broadly.

19 16. Influenza is caused by infection with the influenza virus, including various strains
20 of influenza A and influenza B. The specific strains that circulate in the human population vary
21 from year to year. The influenza virus is readily transmitted from person to person via respiratory
22 secretions produced by coughing and sneezing, with the infections showing marked seasonality in
23 temperate countries like the U.S., such that influenza occurs only in the late fall, winter, and early
24 spring (hence “flu season”), although the timing of the beginning and end of influenza season can
25 vary substantially from one year to the next. While infection with and transmission of influenza
26 virus are most common among children, it is the very young, the very old, and those with a
27 variety of underlying medical conditions (*e.g.* cardiovascular disease, pulmonary disease, etc.)
28 who are most likely to develop severe influenza and its complications and to be hospitalized and

1 to die of the disease as a result.⁵

2 17. Beyond pneumonia and related infections and deaths due to respiratory tract
3 infections, influenza has been shown to cause a substantial increase in the risk of strokes, heart
4 attacks, worsening congestive heart failure, and other adverse health outcomes, leading to
5 substantial morbidity, hospitalization, healthcare costs, and deaths beyond what is directly
6 attributable to influenza infections of the respiratory tract. While the burden of illness,
7 hospitalization, and death due to influenza varies from year to year, the CDC has estimated that
8 during the 2017-2018 influenza season, influenza caused 45 million illnesses, 810,000
9 hospitalizations, and 61,000 deaths in the U.S. alone.⁶ In the absence of influenza vaccination,
10 even with only 40% of the U.S. population choosing to be vaccinated that year and the vaccine
11 being only partially protective, the CDC has estimated that an additional 6.2 million illnesses,
12 91,000 hospitalizations, and 5,700 deaths would have occurred during the 2017-2018 influenza
13 season in the U.S.

14 18. Because the influenza virus changes very rapidly, and no universal influenza
15 vaccine yet exists, influenza vaccine has to be formulated and given annually, based on the best
16 available evidence concerning which strains of influenza A and B virus will be circulating in the
17 upcoming influenza season. While most doses of influenza vaccine given in the U.S. each year
18 are inactivated (*i.e.* killed), a live attenuated form of the vaccine is also available for use in certain
19 populations, as are higher potency vaccines that are recommended for use in the elderly. Based on
20 extensive studies and evidence concerning the burden of influenza-related morbidity and
21 mortality, as well as healthcare costs and other costs to society, and on the extensive evidence that
22 influenza vaccines are very safe, the Advisory Committee on Immunization Practices (ACIP) of
23 the U.S. CDC, the U.S. Preventive Services Task Force, and many clinical organizations'

24
25 ⁵ See, e.g., Panhwar, Muhammad S., "Effect of Influenza on Outcomes in Patients With Heart
26 Failure," *JACC: Heart Failure*, 2019 Feb., 7(2) (Jan. 2, 2019); Ciszewski, Andrzej,
"Cardioprotective effect of influenza and pneumococcal vaccination in patients with
cardiovascular diseases," *Vaccine* (Jan. 4, 2018).

27 ⁶ CDC, "2017-2018 Flu Season: Burden and Burden Averted by Vaccination," available at
28 <https://www.cdc.gov/flu/about/burden-averted/2017-2018.htm> (last accessed Sept. 27, 2020); see
also Rolfes, Melissa A., *et al.*, "Effects of Influenza Vaccination in the United States During the
2017-2018 Influenza Season," *Clinical Infectious Diseases* (Feb. 2, 2019).

1 advisory groups recommend annual influenza immunization of everyone old enough to receive
2 the vaccine, including pregnant women.

3 19. Many millions of doses of influenza vaccine have been given to children, adults,
4 the elderly, and pregnant women over the past more than 60 years, and numerous carefully done
5 epidemiological studies have shown that influenza vaccine and vaccination in all of these groups
6 has an excellent safety profile. Moreover, not only is the influenza vaccine safe for pregnant
7 women, health experts recommend that pregnant women receive the influenza vaccine to protect
8 them from the risk of influenza-associated acute respiratory infection.⁷ Vaccination of pregnant
9 women is seen as important both to protect the pregnant woman herself, because influenza during
10 pregnancy can threaten the life of the woman and the fetus, and to protect the newborn baby prior
11 to the age at which the baby can be vaccinated.⁸ A recent study showed that the influenza vaccine
12 reduced a pregnant woman's risk of being hospitalized with influenza by an average of 40
13 percent.⁹ In sum, the influenza vaccine is safe for the UC population of students, faculty, and staff
14 affected by the Executive Order at issue in this case.

15 20. The scientific and public health consensus is that the influenza vaccine is effective
16 in preventing illnesses, hospitalizations, and deaths caused by influenza virus.¹⁰ Vaccine
17 effectiveness can vary by season, influenza virus strain in the vaccine, age of the recipient, the
18 presence of underlying medical conditions, and other factors. While influenza vaccines are
19 typically less effective than many of the other vaccines routinely given in the U.S., they are the

20 ⁷ Kim, Sara S., *et al.*, "Effects of Prior Season Vaccination on Current Season Vaccine
21 Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012-2013 Through 2017-
2018," *Clinical Infectious Diseases* (June 1, 2020).

22 ⁸ Foo, Damien Y.P., *et al.*, "Early Childhood Health Outcomes Following In Utero Exposure to
23 Influenza Vaccines: A Systematic Review," *Pediatrics*, Vol. 146 2 (Aug. 2020); Munoz, Flor M.
24 and Long, Sarah S., "The Safety of Maternal Influenza Vaccination and Infant Health Outcomes,"
25 *Pediatrics* Vol. 146 (July 27, 2020); Thompson, Mark G., *et al.*, "Influenza Vaccine Effectiveness
26 in Preventing Influenza-associated Hospitalizations During Pregnancy: A Multi-country
27 Retrospective Test Negative Design Study, 2010-2016," *Clinical Infectious Diseases* (Oct. 11,
28 2018).

⁹ Thompson, Mark G., "Influenza Vaccine Effectiveness in Preventing Influenza-associated
Hospitalizations During Pregnancy: A Multi-country Retrospective Test Negative Design Study,
2010-2016," *Clinical Infectious Diseases*, available at
<https://academic.oup.com/cid/article/68/9/1444/5126390> (last accessed Sept. 26, 2020).

¹⁰ Thompson, Mark G., *et al.*, "Influenza vaccine effectiveness in preventing influenza-associated
intensive care admissions and attenuating severe disease among adults in New Zealand 2012-
2015," *Vaccine*, Vol. 36, Issue 39 (Sept. 18, 2018).

1 most effective tool available for reducing the number of influenza illnesses, hospitalizations and
2 deaths each year. In the 2018-2019 influenza season, the influenza vaccine prevented an
3 estimated 4.4 million influenza illnesses, 2.3 million influenza-associated medical visits, 58,000
4 influenza-associated hospitalizations, and 3,500 influenza-associated deaths.¹¹ Importantly, even
5 in years when the vaccine has relatively low effectiveness, influenza vaccines are effective in
6 reducing severity and morbidity from influenza. The utility of influenza vaccines generally can be
7 inferred from the recommendations for the widespread vaccination of people throughout the
8 medical profession for decades at both the state and federal level.

9 21. Hesitancy to routine influenza vaccination lacks a basis in the science and is often
10 based on misinformation or lack of information. However, despite the existence of vaccine
11 hesitancy more broadly, the vast majority of the population understands that the potential risks
12 posed by influenza vaccination are rare and outweighed by the significant benefits of reducing
13 influenza-related complications, hospitalizations, and deaths. Critically, contrary to Plaintiffs' and
14 Plaintiffs' declarants' assertions, the fact that not everyone gets an influenza shot on a regular
15 basis is not evidence of vaccine hesitancy or legitimate and founded public skepticism over
16 efficacy. Rather, other variables such as adequate access to preventative healthcare in the U.S.
17 account for the discrepancy between the number of people who should receive the influenza
18 vaccine and those who do.

19 ***The Executive Order Mandating Influenza Vaccine***

20 22. I support the University's influenza vaccine mandate as an important public health
21 measure for protecting the health and safety of students, faculty, and staff on UC campuses. There
22 is no question from a medical and public health standpoint that anything that can be done to
23 reduce the impact of influenza illness on hospitals and healthcare workers can mitigate the impact
24 of COVID-19 on these institutions and healthcare workers. Other measures, such as social
25 distancing accomplished in part by UC's policy to move its curriculum to primarily remote

26
27 ¹¹ CDC, "Vaccine Effectiveness: How Well Do the Flu Vaccines Work?," available at
28 <https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm> (last accessed Sept. 26, 2020); *see also*
Chung, Jessie R., *et al.*, "Effects of Influenza Vaccination in the United States During the 2018-
2019 Influenza Season," *Clinical Infectious Diseases* (Jan. 6, 2020).

1 instruction and the mandated use of masks on campus, are also good precautionary measures. But
2 each of these measures is imperfect and cannot, alone, prevent the effects of the COVID-19
3 pandemic from becoming worse. The best advice by experts is that these measures should be
4 overlapping and used in concert.

5 23. From an epidemiological perspective, it is virtually certain that there will be
6 COVID-19 and influenza circulating simultaneously this winter. The fact that influenza seasons
7 are not as bad in some years tells us nothing about what to expect in the approaching influenza
8 season. Because we do not know what influenza virus strains will be circulating or their
9 properties, how pathogenic they will be, or what the morbidity/mortality will be this year, it is
10 incumbent on public health officials to mitigate the effects of influenza, including ensuring that
11 there is widespread influenza vaccination.

12 24. I have reviewed the declarations of Plaintiffs' declarants, Peter Gotzsche, M.D.,
13 Peter Doshi, Ph.D., Tom Jefferson, M.D., Laszlo Boros., M.D., and Andrew Noymer, Ph.D.
14 Several of their opinions stand out as being particularly misleading and contrary to the weight of
15 scientific authority. *First*, there is no support in any serious peer-reviewed scientific journal to
16 support the opinion that the influenza vaccine is unsafe or ineffective. All the preeminent clinical
17 and public health experts in the world agree that the influenza vaccine is safe and reasonably
18 effective, notwithstanding the fact that the influenza vaccine is more effective in some years than
19 in others. Similarly, the medical and public health consensus is that, in any given year, the use of
20 the influenza vaccine prevents large numbers of avoidable infections, hospitalizations, and deaths.
21 *Second*, Plaintiffs overstate the ineffectiveness of the influenza vaccine amongst seniors, overstate
22 the safety risks to seniors, and ignore the fact that the UC target population overwhelmingly
23 consists of individuals under the age of 65. *Third*, Plaintiffs and the declarants' opinions
24 regarding safety and efficacy of the influenza vaccination for pregnant women are contrary to the
25 best medical and public health advice. In fact, as discussed above, pregnant women should
26 receive the influenza vaccine to protect themselves and the fetus and eventually the newborn baby
27 through the age of six months. As with adults over age 65, the number of pregnant women on a
28 university campus is also exceedingly low. And *fourth*, to the extent that Plaintiffs and the


1 declarants opine that the influenza vaccine does not directly prevent COVID-19, that point is not
2 controversial, as a vaccine is generally only effective against the target virus; however, Plaintiffs
3 and Plaintiffs' declarants ignore the larger point that reducing the impact of an influenza outbreak
4 will assist public health officials in combatting the effects of the COVID-19 pandemic by
5 preventing symptom confusion and alleviating the strain on healthcare systems and supplies.

6 I declare under penalty of perjury under the laws of the State of California that the
7 foregoing is true and correct to the best of my knowledge.

8 Executed in Berkeley, California, on this 29th day of September 2020.

9

10


Arthur L. Reingold, M.D.

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

EXHIBIT A

August, 2020

CURRICULUM VITA

Arthur Lawrence Reingold

PRESENT POSITION: Professor of Epidemiology
Division Head, Epidemiology
School of Public Health
University of California, Berkeley
2121 Berkeley Way, #5302
Berkeley, California 94720-7360
Phone: [REDACTED]
Fax: [REDACTED]
E-mail: [REDACTED]

DATE OF BIRTH: October 31, 1948

PLACE OF BIRTH: Chicago, Illinois

MARITAL STATUS: Married

EDUCATION: 1966 - 70 A.B. University of Chicago
1970 - 76 M.D. University of Chicago

POSTGRADUATE TRAINING: 1976 - 78 Internal Medicine Resident, Mount Auburn Hospital
Cambridge, Massachusetts
1980 - 82 Preventive Medicine Resident, Centers for Disease
Control (CDC) - Atlanta, Georgia

POSITIONS HELD: 1979 - 80 Epidemic Intelligence Service Officer,
State of Connecticut - Department of Health Services
Hartford, Connecticut
1980 - 81 Epidemic Intelligence Service Officer,
Special Pathogens Branch - Bacterial Diseases Division
Centers for Disease Control (CDC) - Atlanta, Georgia
1981 - 85 Assistant Chief, Respiratory & Special Pathogens
Epidemiology Branch, Center for Infectious Diseases
Centers for Disease Control (CDC) - Atlanta, Georgia
1985 - 87 CDC Liaison Officer, Office of the Director
Centers for Disease Control - Atlanta, Georgia

FACULTY APPOINTMENTS: 1979 - 80 Instructor, Department of Medicine (Epidemiology)
University of Connecticut - Hartford, Connecticut
1985 - 87 Visiting Lecturer, Department of Biomedical and
Environmental Health Sciences (Epidemiology)
University of California, Berkeley
1987 - Professor of Epidemiology, School of Public Health,
University of California, Berkeley
1989 - Professor, Department of Epidemiology and
Biostatistics - University of California, San Francisco

Arthur Lawrence Reingold

FACULTY APPOINTMENTS (CONTINUED)	1990 - 94	Head, Epidemiology Program, Department of Biomedical and Environmental Health Sciences, University of California, Berkeley
	1991 -	Clinical Professor, Department of Medicine University of California, San Francisco
	1994 - 2000	Head, Division of Public Health Biology and Epidemiology University of California, Berkeley
	2000 - 2018	Head, Division of Epidemiology, School of Public Health, University of California, Berkeley
	2018 -	Head, Division of Epidemiology and Biostatistics, School of Public Health University of California, Berkeley
	2008 - 2014	Associate Dean for Research, School of Public Health, University of California, Berkeley
	2009 - 2014	Edward Penhoet Distinguished Chair for Global Health and Infectious Disease

MEDICAL LICENSURE: California

**BOARD
CERTIFICATION:** 1980 American Board of Internal Medicine

AWARDS: 1970 - 74 Medical Scientist Training Program
1985 Commendation Medal, U.S. Public Health Service
1986 Charles Shepard Award, Centers for Disease Control (CDC)

MEMBERSHIPS: 1970 Sigma Xi
1978 American College of Physicians
1983 American Society for Microbiology
1984 Society for Epidemiologic Research
1986 Infectious Disease Society of America (Fellow)
1988 American Epidemiological Society
1991 American College of Epidemiology (Fellow)
1994 AAAS (Fellow)
2003 Institute of Medicine, National Academy of Medicine (Member)

PROFESSIONAL ACTIVITIES

CONSULTATIONS: 1981 Institute of Medicine: Toxic-shock syndrome
1981 Food and Drug Administration: Toxic-shock syndrome
1982 United States Agency for International Development:
Control of meningococcal meningitis in West Africa
1983 World Health Organization (WHO):
Control of meningococcal meningitis in Nepal
1983 East-West Center, University of Hawaii: Role of indoor air pollution
in acute respiratory infections in developing countries
1984 Institute of Medicine: Meningococcal vaccines

Arthur Lawrence Reingold

**CONSULTATIONS
(CONTINUED)**

1986	World Health Organization (WHO): Control of meningococcal meningitis in South Asia
1987 - 1993	Center for Child Survival, University of Indonesia: Control of Acute Respiratory Infections
1988	Evaluation of the Combating Communicable Childhood Disease Program, Ivory Coast
1994	Evaluation of National Epidemiology Board Program, Rockefeller Foundation
1995	Planning of a School-based Acute Rheumatic Fever Prevention Project - New Zealand Heart Foundation
1995	Vaccines Advisory Committee, Food & Drug Administration Approval of acellular pertussis vaccine
1996	External Reviewer, NIAID Group B Streptococcus Research Contract with Harvard University
1996 - 2000	U.S. Food and Drug Administration; Consultant to the Vaccines Advisory Committee
1996	World Health Organization, Consultation on Control of Meningococcal Meningitis in Africa
1998 - 2002	Advisor to the INCLIN "Indiaclen" project
2002 - 2003	Evaluation of a School-based Acute Rheumatic Fever Prevention Project - New Zealand Heart Association

**ADVISORY BOARDS
AND PANELS:**

1988 - 1989	Member, Advisory Committee on Ground Water and Reproductive Outcomes, State of California Department of Health Services
1989 - 1990	AIDS Advisory Committee, Alameda County Board of Supervisors
1989 - 1993	Advisory Committee, Birth Defects Monitoring Program, State of California Department of Health Services
1993 - 1995	Centers for Disease Control (CDC): Public Health Service Advisory Panel on the Case Definition for Lyme Disease
1992 - 1994	World Health Organization (WHO): Task Force on Strengthening Epidemiologic Capacity; Childhood Vaccine Initiative
1996 - 2000	Armed Forces Epidemiological Board
1997 - 2012	University of California, San Francisco AIDS Research Institute Steering Committee
1998 - 2003	Emerging Infections Committee of the Infectious Diseases Society of America
1998 - 2000	Panelist, Howard Hughes Medical Institute Predoctoral Fellowship
2001 - 2006	Technical expert, Sub-Committee on the Protection of Public Health; California State Strategic Committee on Terrorism

Arthur Lawrence Reingold

ADVISORY BOARDS PANELS (CONTINUED)	2003 - 2008	Advisory Board, Chinese University of Hong Kong – Centre for Emerging AND Infectious Diseases
	2004 -	Advisory Board, University of California, Berkeley Clinical Research Center
	2004 - 2008	Advisory Board, New York University School of Medicine Fellowship in Medicine and Public Health Research
	2004 - 2005	Institute of Medicine Committee on Measures to Enhance the Effectiveness of CDC Quarantine Station Plan for U.S. Ports of Entry
	2005 - 2012	Strategic Advisory Group of Experts (SAGE) for Vaccine Policy, World Health Organization (WHO) (Deputy Chairman, 2010-2012)
	2005 -	Data and Safety Monitoring Committee; F.I. Proctor Foundation, University of California, San Francisco (UCSF)
	2007 - 2012	NIH Fogarty International Center External Advisory Board
	2007 - 2009	Chair, Working Group on Pneumococcal Vaccine, Strategic Advisory Group of Experts (SAGE), World Health Organization (WHO)
	2008 - 2012	Working Group on H5N1 Influenza Vaccines, Strategic Advisory Group of Experts (SAGE), World Health Organization (WHO)
	2008 - 2011	Chair, Leptospirosis Burden Epidemiology Reference Group, World Health Organization (WHO)
	2008 - 2012	National Biosurveillance Advisory Subcommittee of the Advisory Committee to The Director, Centers for Disease Control and Prevention (CDC)
	2008 - 2009	Institute of Medicine Committee on the Review of Priorities in the National Vaccine Plan
	2009 - 2012	Chair, Working Group on Hepatitis A Vaccine, Strategic Advisory Group of Experts (SAGE), World Health Organization (WHO)
	2011 - 2013	Member, Institute of Medicine Committee on Vaccine Priorities
	2011 - 2014	Member, Working Group on Vaccine Hesitancy, Strategic Advisory Group of Experts (SAGE), World Health Organization (WHO)
	2012 - 2014	Chair, Review of the Heterologous Effects of Childhood Vaccines, World Health Organization (WHO)
	2012 - 2014	Chair, External Review of the Measles Rubella Initiative (of WHO, CDC, UNICEF, American Red Cross, and United Nations Foundation)
	2013 - 2018	Advisory Committee on Immunization Practices (ACIP), U.S. Department of Health and Human Services
	2016 - 2017	Member, Institute of Medicine Committee on a National Strategy for the Elimination of Hepatitis B and C
	2018 - 2019	Member, Independent Review Committee, Global Alliance for Vaccines and Immunizations (GAVI)

Arthur Lawrence Reingold

ADVISORY BOARDS PANELS (CONTINUED)	2018 -	Member, Strategic Advisory Group, Partnership for Influenza Vaccination Introduction
	2020	Member, Organizing Committee, National Academics of Science, Engineering, and Medicine (NASEM) Workshop on Airborne Transmission of SARS-CoV-2
	2020	Member, National Academies of Science, Engineering, and Medicine (NASEM) Committee on Equitable Allocation of Vaccines for the Novel Coronavirus

LEADERSHIP POSITIONS:

1997 - 2012	Secretary-Treasurer, American Epidemiological Society
2009 - 2010	President, Society for Epidemiologic Research
2015 – 2016	President, American Epidemiological Society (AES)

EDITORIAL BOARDS:

1995 - 2000	Board of Editors, American Journal of Epidemiology
2001 - 2005	Board of Editors, Epidemiology
2005 -	Editorial Advisory Board, Global Public Health
2009 - 2010	Editorial Advisory Board, American Journal of Epidemiology

ASSOCIATE EDITORSHIPS:

2017 - 2019	Current Epidemiology Reports
2018 -	Vaccine

Arthur Lawrence Reingold

PUBLICATIONS:

1. Hayes RV, Pottenger LA, Reingold AL, Getz GS, Wissler RW. Degradation of I¹²⁵ - labeled serum low density lipoprotein in normal and estrogen-treated male rats. *Biochem Biophys Res Comm* 1971;44:1471-1477.
2. Reingold AL, Kane MA, Murphy BL, Checko P, Francis DP, Maynard JE. Transmission of hepatitis B by an oral surgeon. *J Infect Dis* 1982;145:262-268.
3. Reingold AL, Dan BB, Shands KN, Broome CV. Toxic-shock syndrome not associated with menstruation: a review of 54 cases. *Lancet* 1982;1:1-4.
4. Bartlett P, Reingold AL, Graham DR, et al. Toxic-shock syndrome associated with surgical wound infections. *JAMA* 1982;247:1448-1450.
5. Reingold AL, Hargrett NT, Shands KN, et al. Toxic-shock syndrome surveillance in the United States, 1980-1981. *Ann Intern Med* 1982;96:875-880.
6. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV. Nonmenstrual toxic-shock syndrome: a review of 130 cases. *Ann Intern Med* 1982;96:871-874.
7. Broome CV, Hayes PS, Ajello GW, Feeley JC, Gibson RJ, Graves LM, Hancock GA, Anderson RJ, Highsmith AK, Mackel DC, Hargrett NT, Reingold AL. In-vitro studies of interactions between tampons and *Staphylococcus aureus*. *Ann Intern Med* 1982;96:959-962.
8. Guinan ME, Dan BB, Guidotti RJ, Reingold AL, et al. Vaginal colonization with *Staphylococcus aureus* in healthy women: a review of four studies. *Ann Intern Med* 1982;96(pt.2):944-947.
9. Schlech WF III, Shands KN, Reingold AL, et al. Risk factors for development of toxic-shock syndrome: association with a tampon brand. *JAMA* 1982;248:835-839.
10. Reingold AL, Bank JD. Legionellosis. In: Easmon CSF, Jeljaszewicz J, eds. *Medical Microbiology*. London: Academic Press 1982 (I):217-239.
11. Reingold AL. Toxic-shock syndrome. In: Spittell JA Jr., ed. *Clinical Medicine*. Philadelphia: Harper & Row Publishers 1982 (II):1-6.
12. Kornblatt AN, Reingold AL. Legionellosis. In: Steele JH, Hillyer RV, Hopla CE, eds. *CRC Handbook Series in Zoonoses*. CRC Press 1982:313-324.
13. Wilkinson HW, Reingold AL, Brake JB, McGiboney DL, Gorman GW, Broome CV. Reactivity of serum from patients with suspected Legionellosis against 29 antigens of legionellaceae and *Legionella*-like organisms by indirect immunofluorescence assay. *J Infect Dis* 1983;147:23-31.
14. Meenhorst PL, Reingold AL, Gorman GW, et al. *Legionella* pneumonia in guinea pigs exposed to aerosols of concentrated potable water from a hospital with nosocomial Legionnaires' disease. *J Infect Dis* 1983;147:129-132.

Arthur Lawrence Reingold

15. Reingold AL. Nonmenstrual toxic-shock syndrome: the growing picture. JAMA 1983; 249:932 (editorial).
16. Reingold AL. Meningococcal meningitis. Nepal Paed Soc J 1983; 2:144-148.
17. Reingold AL, Broome CV, Phillips CJ, Meda H, Tiendrebeogo H, Yada A. Evidence of continuing protection against group A meningococcal disease one year after vaccination: a case-control approach. Med Trop 1983;43:225.
18. Reingold AL, Kane MA, Hightower AW. Disinfection procedures and infection control in the outpatient oral surgery practice. J Oral Maxillofac Surg 1984;42:568-572.
19. Broome CV, Reingold AL. Current issues in toxic-shock syndrome. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases. McGraw Hill 1984;65-85.
20. Herwaldt LA, Gorman GW, McGrath T, Toma S, Brake B, Hightower AW, Jones J, Reingold AL, et al. A new Legionella species, Legionella feeleyi species nova, causes Pontiac fever in an automobile plant. Ann Intern Med 1984;100:333-338.
21. Ajello GW, Feeley JC, Hayes PS, Reingold AL, Bolan G, et al. Trans-isolate medium: a new medium for primary culturing and transport of Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae. J Clin Microbiol 1984;20:55-58.
22. Hayes PS, Graves LM, Feeley JC, Hancock GA, Cohen ML, Reingold AL, et al. Production of toxic-shock-associated protein(s) in Staphylococcus aureus strains isolated from 1956 through 1982. J Clin Microbiol 1984;20:42-46.
23. Reingold AL, Thomason BM, Brake BJ, Thacker L, Wilkinson HW, Kuritsky JN. Legionella pneumonia in the United States: the distribution of serogroups and species causing human illness. J Infect Dis 1984;149:819.
24. Blaser M, Reingold AL, Alsever RN, Hightower A. Primary meningococcal pericarditis: A disease of adults associated with serogroup C Neisseria meningitidis. Rev Infect Dis 1984;6:625-632.
25. Jones EE, Alford PL, Reingold AL, et al. Predisposition to invasive pneumococcal illness following parainfluenza type 3 virus infection in chimpanzees. JAVMA 1984;185:1351-1353.
26. Reingold AL, Thomason BM, Kuritsky J. Results of Legionnaires' disease direct fluorescent-antibody testing at Centers for Disease Control, 1980-1982. In: Thornsberry C, Balows A, Feeley JC, and Jakubowski J, eds. Legionella, ASM 1984;21-22.
27. Kuritsky JN, Reingold AL, Hightower AW, Broome CV. Sporadic Legionellosis in the United States, 1970 to 1982. In: Thornsberry C, Balows A, Feeley JC, and Jakubowski J, eds. Legionella, ASM 1984;243-245.
28. Fleming DW, Reingold AL. Legionella. In: Braude AI ed. Medical Microbiology and Infectious Diseases, Second Edition W.B. Saunders 1985;352-358.

Arthur Lawrence Reingold

29. Garbe PL, Arko RJ, Reingold AL, et al. *Staphylococcus aureus* isolates from patients with non-menstrual Toxic Shock Syndrome: Evidence for Additional Toxins. *JAMA* 1985;253:2538-2542.
30. Garbe PL, Davis BJ, Weisfeld J, Markowitz L, Miner P, Garrity F, Barbaree JM, Reingold AL. Nosocomial Legionnaires' Disease: Epidemiologic Demonstration of Cooling Towers as a Source. *JAMA* 1985;254:521-524.
31. Fleming DW, Cochi SL, MacDonald KL, Brondum J, Haves PS, Plikaytis BD, Holmes MB, Audurier A, Broome CV, Reingold AL. Pasteurized milk as a vehicle of infection in an outbreak of listeriosis. *NEJM* 1985;312:404-407.
32. Meenhorst P, Reingold AL, Groothuis DL, et al. Water-related nosocomial pneumonia caused by *Legionella pneumophila* serogroups 1 and 10. *J Infect Dis* 1985;152:356-364.
33. Bolan G, Reingold AL, Carson L, et al. Infections with *Mycobacterium chelonae* in patients receiving dialysis and using processed hemodialyzers. *J Infect Dis* 1985;152:1013-1019.
34. Reingold AL. Toxic-shock in the United States of America: epidemiology. *Postgrad Med J* 1985;61:21-22.
35. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. *Lancet* 1985;II:114-118.
36. Petitti DB, Reingold AL, Chin J. The incidence of toxic-shock syndrome in Northern California: 1972-1983. *JAMA* 1986;255:368-372.
37. Reingold AL. Toxic-shock syndrome and the contraceptive sponge. *JAMA* 1986;255:242-243 (editorial).
38. Berkley S, Reingold AL. Toxic-shock syndrome. In: Kass EH and Platt R, eds. *Current Therapy in Infectious Disease*. B.C. Decker, Inc. 1986;78-81.
39. Reingold AL. Toxic-shock syndrome. In: Wheat J and White A, eds. *Infectious Diseases*, University of Chicago Press, 1986.
40. Reingold AL, Broome CV. Nosocomial central nervous system infections. In: Bennett JV, Brachman PS, eds. *Hospital Infections*. Little Brown & Co. 1986;521-529.
41. Markowitz L, Reingold AL. Toxic-shock syndrome. In: Maxcy-Rosenau Public Health and Preventive Medicine, 12th edition Appleton-Century-Crofts 1986;456-459.
42. Reingold AL, Xiao DL, Plikaytis B, Ajello L. Systemic mycoses in the United States, 1980-1982. *J Med Vet Mycol* 1986;24:433-436.
43. Cochi SL, Markowitz L, Owens Jr RC, Stenhouse DH, Regmi DN, Shrestha RPB, Acharya IL, Manandhar M, Gurubacharya VL, Owens D, Reingold AL. Control of epidemic group A meningococcal meningitis in Nepal. *Int J Epid* 1987;16:91-97.
44. Markowitz LE, Hightower AW, Broome CV, Reingold AL. Toxic-shock syndrome: Evaluation of national surveillance data using a hospital discharge survey. *JAMA* 1987;258:75-78.

Arthur Lawrence Reingold

45. Berkley SF, Hightower AW, Reingold AL, Broome CV. The relationship of tampon characteristics to menstrual toxic-shock syndrome. *JAMA* 1987;258:917-920.
46. Reingold AL, Kane MA, Hightower AW. Failure of gloves and other protective devices to prevent transmission of hepatitis B virus in oral surgeons. *JAMA* 1988;259:2558-2560.
47. Reingold AL. The role of Legionellae in acute infections of the lower respiratory tract. *Rev Infect Dis* 1988;10(5):1018-1028.
48. Harrison LH, Broome CV, Hightower AW, Hoppe CC, Makintubee S, Sitze SL, Taylor JA, Gaventa S, Wenger JD, Facklam RR, and the *Haemophilus Vaccine Efficacy Study Group* (includes A.L. Reingold). A day-care based study of the efficacy of *Haemophilus influenzae* B polysaccharide vaccine. *JAMA* 1988;260(10):1413-1418.
49. Schwartz B, Broome CV, Hightower AW, Brown GR, Ciesielski CA, Gaventa S, Gellin BG, Mascola L, and the *Listeriosis Study Group* (includes A.L. Reingold). Association of sporadic listeriosis with consumption of uncooked hot dogs and undercooked chicken. *Lancet* 1988;II:779-782.
50. Carson LA, Bland LA, Cusick LB, Favero MS, Bolan G, Reingold AL, et al. Prevalence of nontuberculous mycobacteria in water supplies of hemodialysis centers. *Appl Environ Micro* 1988;54:3122-3125.
51. Petitti DB, Reingold AL. Update through 1985 on the incidence of toxic shock syndrome among members of a prepaid health plan. *Rev Infect Dis* 1989;11:S22-27.
52. Reingold AL, Broome CV, Gaventa S, Hightower SW, and the Toxic-Shock Syndrome Study Group. Risk factors for menstrual toxic-shock syndrome: results of a multi-state case-control study. *Rev Infect Dis* 1989;11:S35-42.
53. Gaventa S, Reingold AL, Hightower AW, et al. Active surveillance for toxic-shock syndrome in the United States, 1986. *Rev Infect Dis* 1989;11:S28-34.
54. Schwartz B, Gaventa S, Broome CV, Reingold AL, et al. Non-menstrual toxic-shock syndrome associated with barrier contraceptives: report of a case-control study. *Rev Infect Dis* 1989;11:S43-49.
55. Reingold AL, Hearst N. Identifying the health care needs of the community. In: Overall N, Williamson J, eds. *Community Oriented Primary Care in Action: A Practice Manual for Primary Care Settings*. U.S. Department of Health and Human Services.
56. Koo D, Bouvier B, Wesley M, Courtright P, Reingold AL. Epidemic keratoconjunctivitis in a university medical center ophthalmology clinic: need for re-evaluation of the design and disinfection of instruments. *Inf Control and Hosp Epi* 1989;10:547-552.
57. Harrison LH, Broome CV, Hightower AW, and the *Haemophilus Vaccine Efficacy Study Group* (includes A.L. Reingold). *Haemophilus influenzae* type b polysaccharide vaccine: an efficacy study. *Pediatrics* 1989;84:225-261.

Arthur Lawrence Reingold

58. Wenger JD, Harrison LH, Hightower A, Broome CV, *Haemophilus influenzae* Study Group (includes A.L. Reingold). Day care characteristics associated with *Haemophilus influenzae* disease. *Am J Public Health* 1990;80:1455-1458.
59. Morrow HW, Slaten DD, Reingold AL, et al. Risk factors associated with a school-related outbreak of serogroup C meningococcal disease. *Pediatric Infect Dis J* 1990;9:394-398.
60. Wenger JD, Hightower AW, Facklam RR, Gaventa S, Broome CV, *Bacterial Meningitis Study Group* (includes A.L. Reingold). Bacterial meningitis in the United States, 1986: Report on a multistate surveillance study. *J Infect Dis* 1990;162:1316-1323.
61. Reingold AL. Toxic-shock syndrome. In: Evans AS, Brachman PS, eds. *Bacterial Infections of Humans*. Plenum, 1991;727-743.
62. Gellin BG, Broome CV, Bibb WF, Weaver RE, Gaventa S, Mascola L, the *Listeriosis Study Group*. (includes A.L. Reingold). The epidemiology of listeriosis in the United States - 1986. *Am J Epi* 1991;133:392-401.
63. Reingold AL. Toxic-shock syndrome. In: Rakel RE, ed. *Conn's Current Therapy*. W. B. Saunders, 1991;1010-1012.
64. Reingold AL, Markowitz LE. Toxic-shock syndrome. In: Maxcy-Rosenau *Public Health and Preventive Medicine*, 13th Edition. Appleton-Century-Crofts, 1991;304-306.
65. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold AL, Manos MM. Genital human papillomavirus infection in female university students as determined by a PCR-based method. *JAMA* 1991;265:472-477.
66. Sutrisna B, Frerichs RR, Reingold AL. Randomised, controlled trial of effectiveness of ampicillin in mild acute respiratory infections in Indonesian children. *Lancet* 1991;338:471-474.
67. Reingold AL. Toxic-shock syndrome: an update. *Am J Ob & Gyn* 1991;165:1236-1239.
68. Pettiti DB, Reingold AL. Recent trends in the incidence of toxic-shock syndrome in Northern California. *Am J Public Health* 1991;81:1209-1211.
69. Ley C, Reingold AL, et al. Determinants of genital human papillomavirus infection in young women. *JNCI* 1991;83:997-1003.
70. Pinner RW, Gellin BG, Bibb WF, Baker CN, Weaver R, Hunter SB, Waterman SH, Mocca LF, Frasch CE, Broome CV, the *Meningococcal Disease Study Group* (includes A.L. Reingold). Meningococcal disease in the United States-1986. *J Infect Dis* 1991;164:368-374.
71. Wenger JD, Pierce R, Deaver KA, Plikaytis BD, Facklam RR, Broome CV, and the *Haemophilus influenzae* Study Group (includes A.L. Reingold). Efficacy of *Haemophilus influenzae* type b polysaccharide-diphtheria toxoid conjugate vaccine in U.S. children aged 18-59 months. *Lancet* 1991; 338:395-398.

Arthur Lawrence Reingold

72. Moore PS, Plikaytis BD, Bolan GA, Oxtoby MJ, Yada A, Zoubga A, Reingold AL, Broome CV. Detection of meningitis epidemics in Africa: a population-based analysis. *International J Epi* 1992;21:155-162.
73. Schuchat A, Deaver KA, Wenger JD, Plikaytis BD, Mascola L, Pinner RW, Reingold AL, Broome CV, and the *Listeria Study Group*. Role of foods in sporadic listeriosis. I. Case-control study of dietary risk factors. *JAMA* 1992;267:2041-2045.
74. Pinner RW, Schuchat A, Swaminathan B, Hayes PS, Deaver KA, Weaver RE, Plikaytis BD, Reeves M, Broome CV, Wenger JD, and the *Listeria Study Group* (includes A.L. Reingold). Role of foods in sporadic listeriosis. II. Microbiologic and epidemiologic investigation. *JAMA* 1992; 267:2046-2050.
75. Wenger JD, Pierce R, Deaver K, Franklin R, Bosley G, Pigott N, Broome CV, and the *Listeria Study Group* (includes A.L. Reingold). Invasive *Haemophilus influenzae* disease: A population-based evaluation of the role of capsular polysaccharide serotype. *J Infect Dis* 1992;165(suppl 1):S34-5.
76. Steinhart R, Reingold AL, Taylor F, Anderson G, Wenger JD. Invasive *Haemophilus influenzae* infections in men with HIV infection. *JAMA* 1992;268:3350-3352.
77. Hayes PS, Graves LM, Swaminathan B, Ajello GW, Malcolm GB, Weaver RE, Ransom R, Deaver K, Plikaytis BD, Schuchat A, Wenger JD, Pinner RW, Broome CV, and the *Listeria Study Group* (includes A.L. Reingold). Comparison of three selective enrichment methods for the isolation of *Listeria monocytogenes* naturally contaminated foods. *J of Food Protection*, 1992; 55:952-959.
78. Osmond DH, Charlebois E, Sheppard HW, Page KA, Winkelstein W Jr, Moss AR, Reingold AL. A comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. *J Infect Dis*, 1993;167:66-71.
79. Osmond DH, Padian N, Sheppard HW, Glass S, Shiboski SC, Reingold AL. Risk factors for hepatitis C virus seropositivity in heterosexual couples. *JAMA* 1993;269:361-365.
80. Tappero JW, Koehler JE, Berger TG, Reingold AL, et al. Bacillary angiomatosis and bacillary splenitis in immunocompetent adults. *Ann Int Med*, 1993;118:363-365.
81. Tappero JW, Mohle-Boetani J, Koehler JE, Reingold AL, et al. The epidemiology of bacillary angiomatosis and bacillary peliosis. *JAMA* 1993;269:770-775.
82. Weinstock HS, Bolan G, Reingold AL, Polish LB. Hepatitis C virus infection among patients attending a clinic for sexually transmitted diseases. *JAMA* 1993;269:392-394.
83. Yajko DM, Nassos PS, Sanders CA, Gonzalez PC, Reingold AL, et al. Comparison of four decontamination methods for recovery of *Mycobacterium avium* complex from stools. *J Clin Micro*, 1993;31:302-306.
84. Adams WG, Deaver KA, Cochi SL, Plikaytis BD, Zell ER, Broome CV, Wenger JD, and the *Haemophilus influenzae Study Group* (includes A.L. Reingold). Decline of childhood *Haemophilus influenzae* type b (Hib) disease in the Hib vaccine era. *JAMA* 1993;269:221-226.

Arthur Lawrence Reingold

85. Sutrisna B, Reingold AL, Kresno S, Harrison G, Utomo. Care-seeking for fatal illnesses in young children in Indramayu, West Java, Indonesia. *Lancet* 1993;342:787-789.
86. Sudarti K, Harrison GG, Sutrisna B, Reingold AL. Acute respiratory infection in children under five years in Indramayu, West Java, Indonesia: a rapid ethnographic assessment. *Medical Anthropology*. 1994;15:1-10.
87. Ley C, Olshen EM, Chin L, Reingold AL. The use of serologic tests for Lyme disease in a prepaid health plan in California. *JAMA* 1994;271:460-463.
88. Ley C, Davila I, Mayer N, Murray R, Reingold AL. Lyme disease in Northwestern coastal California. *Western J Med*, 1994;160:534-539.
89. Chin DP, Reingold AL, Stone EN, Vittinghoff E, Horsburgh Jr CR, et al. The impact of *Mycobacterium avium* complex bacteremia and its treatment on survival of AIDS patients-a prospective study. *J Infect Dis* 1994;170:578-584.
90. Horsburgh CR, Chin DP, Yajko DM, Hopewell PC, Reingold AL, et al. Environmental risk factors for acquisition of *Mycobacterium avium* complex in persons with human immunodeficiency virus infection. *J Infect Dis* 1994;170:362-367.
91. Chin DP, Reingold AL, Horsburgh CR, Yajko DM, et al. Predicting *Mycobacterium avium* complex bacteremia in patients with human immunodeficiency virus - a prospectively validated model. *Clin Infect Dis* 1994;19:668-674.
92. Chin DP, Hopewell PC, Yajko DM, Vittinghoff E, Horsburgh CR, Hadley WK, Stone EN, Nassos PS, Ostroff SM, Jacobson MA, Matkin CC, Reingold AL. *Mycobacterium avium* complex in the respiratory or gastrointestinal tract and the risk of *M. avium* complex bacteremia in patients with human immunodeficiency virus infection. *J Infect Dis* 1994;169:289-295.
93. Jackson LA, Tenover FC, Baker C, Plikaytis BD, Reeves MW, Stocker SA, Weaver RE, Wenger JD, and the *Meningococcal Disease Study Group* (includes A.L. Reingold). Prevalence of *Neisseria meningitidis* relatively resistant to penicillin in the United States, 1991. *J Infect Dis* 1994; 169:438-441.
94. Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD, and the Active Surveillance Study Group (includes A.L. Reingold). Multistate case-control study of maternal risk factors for neonatal Group B streptococcal disease. *Pediatric Infect Dis J* 1994; 13:623-629.
95. Weinstock HS, Bolan G, Moran JS, Peterman TA, Polish L, Reingold AL. Routine hepatitis B immunization in a clinic for sexually transmitted diseases. *AJPH* 1995;85:846-849.
96. Wang F, So Y, Vittinghoff E, Malani H, Reingold A, et al. Incidence proportion of and risk factors for AIDS patients diagnosed with HIV dementia, central nervous system toxoplasmosis, and cryptococcal meningitis. *J AIDS* 1995;8:75-82.
97. Espinal M, Reingold AL, Koenig E, Lavandera M, Sanchez S. Screening for active tuberculosis in HIV testing centre. *Lancet* 1995;345:890-893.

Arthur Lawrence Reingold

98. Yajko DM, Chin DP, Gonzalez PC, Nassos PS, Hopewell PC, Reingold AL, et al. *Mycobacterium avium* complex in water, food, and soil samples collected from the environment of HIV-infected individuals. *J AIDS* 1995;9:176-182.
99. Lurie P, Fernandes M, Hughes V, Arevalo E, Hudes E, Reingold A, et al. Socioeconomic status and risk for HIV-1, syphilis and hepatitis B infection among sex workers in São Paulo State, Brazil. *AIDS* 1995 9(suppl 1):S31-S37.
100. Jackson L, Hilsdon R, Farley M, Harrison L, Reingold A, et al. Risk factors for Group B streptococcal disease in adults. *Ann Int Med* 1995;123:415-420.
101. Tappero J, Schuchat A, Deaver K, Mascola L, Wenger JD, and the Listeriosis Study Group (includes A.L. Reingold). Reduction in the incidence of human listeriosis in the United States – Effectiveness of prevention efforts? *JAMA* 1995;273:1118-1122.
102. Brandt ME, Hutwagner LC, Kuykendall RJ, Pinner RW, and the Cryptococcal Disease Active Surveillance Group (includes A.L. Reingold). Comparison of multilocus enzyme electrophoresis and random amplified polymorphic DNA analysis for molecular subtyping of *Cryptococcus neoformans*. *J Clin Microbiol* 1995;33:1890-1895.
103. Ley C, Olshen EM, Reingold AL. Case-control study of risk factors for incident Lyme disease in California. *Am J Epi* 1995;142; Suppl:S39-S47.
104. Espinal MA, Reingold AL, Lavandera M. Effect of pregnancy on the risk of developing active tuberculosis. *J Inf Dis* 1996;173:488-491.
105. Perkins BA, Flood JM, Danila R, Holman RC, Reingold AL, et al. Unexplained deaths due to possibly infectious causes in the United States: Defining the problem and design of surveillance and laboratory approaches. *Emerg Inf Dis* 1996;Vol 2:47-53.
106. Hessol NA, Priddy FH, Bolan G, Baumrind N, Vittinghoff E, Reingold AL, Padian NS. Management of pelvic inflammatory disease by primary care physicians: A comparison with Centers for Disease Control and Prevention guidelines. *Sex Trans Dis* 1996;Mar-Apr:157-163.
107. Mohle-Boetani JC, Koehler JE, Berger TG, LeBoit PE, Kemper CA, Reingold AL, et al. Bacillary angiomatosis and bacillary peliosis in patients infected with human immunodeficiency virus: Clinical characteristics in a case-control study. *Clin Inf Dis* 1996;22:794-800.
108. Espinal MA, Reingold AL, Pérez G, et al. Human immunodeficiency virus infection in children with tuberculosis in Santo Domingo, Dominican Republic: Prevalence, clinical findings, and response to antituberculosis treatment. *J AIDS* 1996;13:155-159.
109. Brandt ME, Hutwagner LC, Klug LA, Baughman WS, Rimland D, Graviss EA, Hamill RJ, Thomas C, Pappas PG, Reingold AL, et al. Molecular subtype distribution of *Cryptococcus neoformans* in four areas of the United States. *J Clin Microbiol*, 1996;34:912-917.
110. Bradford WZ, Martin JN, Reingold AL, et al. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. *Lancet* 1996;348:928-931.

Arthur Lawrence Reingold

111. Passaro DJ, Waring L, Armstrong R, Bolding F, Bouvier B, Rosenberg J, Reingold AL, et al. Beauty and the beast: Postoperative *Serratia marcescens* wound infections traced to an out-of-hospital source. *J Inf Dis* 1997;175:992-995.
112. Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley MM, and the *Haemophilus influenzae* Study Group (includes A.L. Reingold). Invasive disease due to *Haemophilus influenzae* serotype f: Clinical and epidemiologic characteristics in the *H. influenzae* serotype b vaccine era. *Clin Inf Dis*, 1996;22:1069-76.
113. Sabino EC, Diaz RC, Brigido LF, Learn GH, Mullins JI, Reingold AL, et al. Distribution of HIV-1 subtypes seen in an AIDS clinic in São Paulo City, Brazil. *AIDS* 1996; 10:1579-1584.
114. Brandt ME, Pfaller MA, Hajjeh RA, Graviss EA, Rees J, Spitzer ED, Pinner RW, Mayer LW, and the Cryptococcal Disease Active Surveillance Group (includes A.L. Reingold). Molecular subtypes and antifungal susceptibilities of serial *Cryptococcus neoformans* isolates in human immunodeficiency virus - associated cryptococcosis. *J Inf Dis* 1996;174:812-820.
115. Whitney CG, Pllikaytis BD, Gozansky WS, Wenger JD, Schuchat A, and the Neonatal Group B Streptococcal Disease Study Group (includes A.L. Reingold). Prevention practices for perinatal group B streptococcal disease: A multi-site surveillance analysis. *Obstet & Gyn* 1997;89:28-32.
116. McFarland W, MvereD, Shandera W, Reingold A. The epidemiology and prevention of transfusion-associated Human Immunodeficiency Virus transmission in Sub-Saharan Africa. *Vox Sanguinis* 1997; 72:85-92.
117. Mazurek GH, Chin DP, Hartman S, Reddy V, Horsburgh Jr, CR, Green TA, Yajko DM, Hopewell PC, Reingold AL, et al. Genetic similarity among *Mycobacterium avium* isolates from blood, stool, and sputum of persons with AIDS. *J Inf Dis* 1997; 176:1-8.
118. Schuchat A, Robinson K, Wenger JD, Harrison LH, Farley M, Reingold AL, et al. Bacterial meningitis in the United States in 1995. *N Eng J Med* 337:970-976, 1997.
119. DeRiemer K, Chin DP, Schechter GF, Reingold AL. Tuberculosis among immigrants and refugees. *Arch Int Med*, 1998; 158:753-760.
120. Glaser CA, Safrin S, Reingold AL, Newman TB. The association between *Cryptosporidium* infection and animal exposure in HIV-infected individuals. *J AIDS* 17:79-82, 1998.
121. Reingold AL. Outbreak investigations: A perspective. *Emerg Inf Dis* 4:21-27, 1998.
122. Bradford WZ, Koehler J, El-Hajj H, Hopewell PC, Reingold AL, et al. Dissemination of *Mycobacterium tuberculosis* across the San Francisco Bay area. *J Inf Dis* 177:1104-1107, 1998.
123. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay Area 1992-1993: Results of population-based laboratory active surveillance. *Clin Inf Dis*, 27:1138-1147, 1998.
124. Ragland DR, Buffler PA, Reingold AL, Syme SL, Winkelstein WW Jr, Buffler M. Disease and injury in California with projections to the year 2007: Implications for medical education. *West J Med*, 168:1-23, 1998.

Arthur Lawrence Reingold

125. Espinal MA, Báez J, Soriano G, Garcia V, Laszlo A, Reingold AL, Sanchez S. Drug-resistant tuberculosis in the Dominican Republic: Results of a nationwide survey. *Int J Tuberc Lung Dis*, 2:490-498, 1998.
126. Bindman AB, Osmond D, Hecht FM, Lehman S, Vranizan K, Keane D, Reingold A, et al. Multistate evaluation of anonymous HIV testing and access to medical care. *JAMA*, 280:1416-1420, 1998.
127. Bloch KC, Zwerling L, Pletcher MJ, Hahn JA, Gerberding JL, Ostroff SM, Vugia DJ, Reingold AL. Incidence and clinical implications of isolation of *Mycobacterium kansasii*: Results of a 5-year, population-based study. *Ann Intern Med* 129:698-704, 1998.
128. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, Pappas PG, Thomas C, Reingold AL, et al. Cryptococcosis: Population-based multistate active surveillance and risk factors in Human Immunodeficiency Virus-infected persons. *J Inf Dis*, 179:449-454, 1999.
129. DeRiemer K, Daley CL, Reingold AL. Preventing tuberculosis among HIV-infected persons: A survey of physicians' knowledge and practices. *Prev Med*, 28:437-444, 1999.
130. Jafari HS, Adams WG, Robinson KA, Plikaytis BD, Wenger JD, and the Haemophilus influenzae Study Group (includes A.L. Reingold). Efficacy of Haemophilus influenzae type b conjugate vaccines and persistence of disease in disadvantaged populations. *AJPH*, 89:364-368, 1999.
131. Fonseca LAM, Reingold AL, Casseb JR, Brigido LFM, Duarte AJS. AIDS incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in São Paulo, Brazil. *J Inf Dis* 28:1156-1160, 1999.
132. Reingold AL, Phares C. Communicable Diseases (chapter). In: *Introduction to International Health* (M. Merson, ed.).
133. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, Baughman WS, Reingold AL, et al. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance. *Clin Inf Dis* 29:1164-1170, 1999.
134. Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Cartter M, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. *J Inf Dis*, 180:1894-1901, 1999.
135. Hajjeh RA, Reingold AL, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: Surveillance update, 1979-1996. *Emerg Inf Dis J* 5:807-810, 1999.
136. Osmond DH, Bindman AB, Vranizan K, Lehman JS, Hecht FM, Keane D, Reingold AL. Name-based surveillance and public health interventions for persons with HIV infection. *Ann Int Med* 131:775-779, 1999.
137. Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. *Emerg Inf Dis* 6:820-823, 1999.

Arthur Lawrence Reingold

138. Reingold AL. Infectious disease epidemiology in the twenty-first century - will it be eradicated or will it re-emerge? *Epi Reviews* 22:57-63, 2000.
139. Kahane SM, Watt JP, Smith NJ, Wight S, Reingold AL, Newell K, et al. Immunization levels and risk factors for low immunization coverage among private practices. *Pediatrics*, 2000;105:73-.
140. Espinal MA, Pérez EN, Báez J, Henriquez L, Fernandez K, Lopez M, Olivo P, Reingold AL. Infectiousness of *Mycobacterium tuberculosis* in HIV-1-infected subjects with tuberculosis: A prospective study. *Lancet* 355:275-280, 2000.
141. Schrag SJ, Zywicki S, Farley M, Reingold AL, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. *New Eng J Med* 342:15-20, 2000.
142. Nuorti JP, Butler JC, Gelling L, Kool JL, Reingold AL, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. *Ann Int Med* 132: 182-190, 2000.
143. Hecht FM, Chesney MA, Lehman JS, Osmond D, Vranizan K, Colman S, Keane D, Reingold A, et al. Does HIV reporting by name deter testing? *AIDS* 14:1801-1808, 2000.
144. Breiman RF, Keller DW, Phelan MA, Sniadack DH, Stephens DS, Rimland D, Farley MM, Schuchat A, Reingold AL. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. *Arch Int Med* 160:2633-2638, 2000.
145. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, et al. Increasing prevalence of multi-drug resistant *Streptococcus pneumoniae* in the United States. *N Engl J Med* 343:1917-1924, 2000.
146. Alpers L, Chrouser K, Halabi S, Moeti T, Reingold A, Binkin N, Kenyon T. Validation of the surveillance system for tuberculosis in Botswana. *Int J Tuberc Lung Dis*, 2000; 4:737-743.
147. Factor SH, Whitney CG, Zywicki S, Schuchat A. for the ABC Surveillance Team (includes Reingold, A.). Effects of hospital policies on the 1996 group B streptococcal consensus guidelines. *Obstet Gynecol* 2000; 95:377-382.
148. Factor SF, Whitney CG, Zywicki SS, Schuchat A, Active Bacterial Core Surveillance Team (includes Reingold, AL). Effects of hospital policies based on 1996 group B streptococcal disease consensus guidelines. *Hospital Policies* 2000; 95:377-382.
149. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damske B, Stefonek K, Barnes B, Patterson J, Zell ER, Schuchat A, Whitney CG for the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network (includes Arthur L. Reingold, MD). Epidemiology of invasive *Streptococcus pneumoniae* Infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. *JAMA* 285:1729-1735, 2001.
150. Rosenstein NE, Emery KW, Werner SB, Kao A, Johnson R, Rogers D, Vugia D, Reingold A, Talbot R, et. al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. *Clin Inf Dis* 32:708-715, 2001.

Arthur Lawrence Reingold

151. Kellam S, Pascopella L, Desmond E, Reingold A, Chin DP. Use of recommended laboratory testing methods among patients with tuberculosis in California. *J Clin Micro* 39:1969-1971, 2001.
152. Mesquita F, Kral A, Reingold A, Bueno R, Trigueiros D, Araujo PJ, and the SMR Collaborative Study Group. Trends of HIV infection among injecting drug users in Brazil in the 1990's - the impact of changes in patterns of drug use. *J AIDS*, 2001; 28:298-302.
153. Mesquita F, Kral A, Reingold A, Haddad I, Sanches M, Turienzo G, Piconez D, Araujo P, Bueno R. Overdoses among cocaine users in Brazil. *Addiction*, 2001; 96:1809-1813
154. Larson JI, Ridzon R, Hannan MM, Conde MB, Mello FCQ, Reingold AL, Daley CL, Kritski AL. Sputum induction vs. fiberoptic bronchoscopy in the diagnosis of tuberculosis. *Am J Respir Crit Care Med*, 2001;163:1279-1280.
155. Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D, Pinner R. Active bacterial core surveillance of the Emerging Infections Program network. *Emerg Inf Dis*, 2001; 7:92-99.
156. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, et al. Trends in antifungal drug susceptibility of *Cryptococcus neoformans* isolates in the United States: 1992 to 1994 and 1996 to 1998. *Antimicrobial Agents and Chemotherapy* 2001;45:3065-3069.
157. Hajjeh RA, Relman D, Cieslak PR, Sofair AN, Passaro D, Flood J, et al. and the Critical Illness Working Group (includes Reingold, AL.). Surveillance for unexplained deaths and critical illnesses due to possibly infectious causes, United States, 1995-1998. *Emerg Inf Dis*, 2002;8:145-153.
158. Huang SS, Labus BJ, Samuel MC, Wan DT, Reingold AL. Antibiotic resistance patterns of bacterial isolates from blood in San Francisco county, 1996-1999. *Emerg Inf Dis*, 2002; 8:195-201.
159. Conde MB, Loivos AC, Rezende VM, Soares SLM, Mello FCQ, Reingold AL, Daley CL, Kritski AL. The yield of sputum induction in the diagnosis of pleural tuberculosis. *Am J Respir and Crit Care Med*, 2002; 167:723-725.
160. Handley MA, Reingold AL, Shiboski S, Padian NS. Incidence of acute urinary tract infection in young women and use of male condoms with and without nonoxynol-9 spermicides. *Epidemiology*, 2002;13:431-436.
161. Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, Schuchat A. for the Active Bacterial Core surveillance (ABCs) of the Emerging Infections Program Network. Trends in the incidence and antimicrobial resistance of early-onset sepsis: Population-based surveillance in San Francisco and Atlanta. *Pediatrics*, 2002;110:690-695.
162. Schrag SJ, Zell ER, Lynfield R, Roome A, Arnold KE, Craig A, Harrison L, Reingold A, Stefonek K, Smith G, Gamble M, Schuchat A for the Active Bacterial Core Surveillance team. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. *New Engl J Med* 2002;347:233-239.

Arthur Lawrence Reingold

163. O'Brien KL, Beall B, Barrett NL, Cieslak P, Reingold A, Farley MM, Danila R, Zell ER, Facklam R, Schwartz B, Schuchat A for the Active Bacterial Core Surveillance team. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. *Clin Infect Dis*, 2002;35:268-276.
164. Morita JY, Zell ER, Danila R, Farley MM, Hadler JH, Harrison LH, Lefkowitz L, Reingold A, Kupronis B, Schuchat A, Whitney CG. Association between antimicrobial resistance among pneumococcal isolates and burden of invasive pneumococcal disease in the community. *Clin Infect Dis*, 2002;35:420-427.
165. Chuang I, Van Beneden C, Beall B, Schuchat A. and the ABCs/EIP network (includes Reingold, A.). Population-based surveillance for postpartum invasive group A streptococcal Infections, 1995-2000. *Clin Infect Dis*, 2002;35:665-670.
166. Passaro DJ, Smith DS, Hett EC, Reingold AL, Daily P, Van Beneden CA, Vugia DJ. Invasive Group A Streptococcal infections in the San Francisco Bay Area, 1989-1999. *Epi&Infect*, 2002; 129:471-478.
167. McCormick AW, Whitney CG, Farley MM, Lynfield R, Harrison LH, Bennett NM, Schaffner W, Reingold A, Hadler J, et al. Geographic diversity and temporal trends of antimicrobial resistance in *Streptococcus pneumoniae* in the United States. *Nature Med* 2003;doi:10.1038/nm839.
168. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. *N Engl J Med* 2003;348:1737-1746.
169. Reingold A. If syndromic surveillance is the answer, what is the question? *Biosecurity & Bioterrorism: Biodefense Strategy, Science, and Practice*. 2003;1:1-5.
170. Koehler JE, Sanchez MA, Tye S, Garrido-Rowland CS, Chen FM, Maurer T, Cooper JL, Olson JG, Reingold AL, Hadley WK, Regnery RR, Tappero JW. Prevalence of *Bartonella* infection among HIV-infected patients with fever. *Clin Inf Dis* 2003;37:559-566.
171. Schrag SJ, Arnorld KE, Mohle-Boetani JC, Lynfield R, Zell ER, Stefonek K, Noga H, Craig AS, Thomson Sanza L, Smith G, Schuchat A, Active Bacterial Core Surveillance Team (includes Reingold AL). Prenatal screening for infectious diseases and opportunities for prevention. *Obstet Gynecol* 2003;102:753-760.
172. King MD, Whitney CG, Parekh F, Farley MM, Active Bacterial Core Surveillance Team/Emerging Infections Program Network (includes Reingold AL). Recurrent invasive pneumococcal disease: A population-based assessment. *Clin Inf Dis* 2003;37:1029-1036.
173. Carvalho HB, Seibel SD, Burattini MN, Massad E, Reingold A. Hepatitis B and C and Syphilis: Vulnerability Related Infections among Institutionalized Disadvantaged Youth in São Paulo, Brazil. *J Bras Doenças Sex Transm* 2003;15:41-45.
174. Louie JK, Hacker JK, Mark J, Gavali SS, Yagi S, Espinosa A, Schnurr D, Cossen CK, Isaacson ER, Glaser CA, Fischer M, Reingold AL, Vugia DJ. SARS and common viral infections, *Emerg Inf Dis*, 2004;10:1143-1146.

Arthur Lawrence Reingold

175. Flanders SA, Stein J, Shochat G, Sellers K, Holland M, Maselli J, Drew WL, Reingold AL, Gonzales. Performance of a bedside c-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. *Amer J Med* 2004;116:529-535.
176. Pascopella L, Kellam S, Ridderhof J, Chin DP, Reingold A, Desmond E, Flood J, Royce S. Laboratory reporting of tuberculosis test results and patient treatment initiation in California. *J Clin Micro*, 2004;42:4209-4213.
177. Nicas M, Hubbard AE, Jones RM, Reingold AL. The infectious dose of variola (smallpox) virus. *Appl Biosafety* 2004;9:118-127.
178. Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, Cieslak PR, Hadler J, Farley MM, Facklam RR, Zell ER, Whitney CG. Impact of childhood vaccination on racial disparities in invasive *Streptococcus pneumoniae* infections. *JAMA*, 2004;291:2197-2203.
179. Facklam R, Elliott J, Shewmaker L, Reingold A. Identification and characterization of sporadic isolates of *Streptococcus pneumoniae* isolated from human infections. *J Clin Micro* 2005; 43:933-937.
180. Heffernan RT, Barrett NL, Gallagher KM, Hadler JL, Harrison LH, Reingold AL, Khoshnood K, Holford TR, Schuchat A. Declining incidence of invasive *Streptococcus pneumoniae* infections among persons living with AIDS in an era of highly-active antiretroviral therapy (HAART), 1995-2000. *J Inf Dis*, 2005;191:2038-2045.
181. Bakyaite N, Dorsey G, Yeka A, Banek K, Staedke SG, Kamya MR, Talisuna A, Kironde F, Nsomba S, Kilian A, Reingold A, Rosenthal PJ, Wabwire-Mangen F. Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: A randomized, multisite trial to guide national policy in Uganda. *Am J Trop Med Hyg* 2005;72:573-580.
182. Pai M, Gokhale K, Joshi R, Dogra S, Kalantri SP, Mendiratta DK, Narang P, Daley CL, Granich RM, Mazurek GH, Reingold AL, Riley LW, Colford Jr, JM. *Mycobacterium tuberculosis* infection in health care worker in rural India: Comparison of whole-blood interferon γ assay with tuberculin skin testing. *JAMA* 2005;293:2746-2755.
183. Pai M, Kalantri S, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampicin resistance in *Mycobacterium tuberculosis*: a meta-analysis. *Journal of Infection* 2005;51:175-187.
184. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, Harrison LH, Schaffner W, Reingold AL, Bennett NM, Hadler J, Cieslak PR, Whitney CG (for the Active Bacterial Core Surveillance Team). Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. *JAMA* 2005;294:2043-2051.
185. Kalantri S, Pai M, Pascopella L, Riley L, Reingold A. Bacteriophage-based tests for the detection of *Mycobacterium tuberculosis* in clinical specimens: a systematic review and meta-analysis. *BMC Inf Dis* 2005;5:59; doi:10.1186/1471-2334-5-59.
186. Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CA for the Active Bacterial Core surveillance/Emerging Infections Program Network (includes Reingold AL). Increased prevalence of pediatric pneumococcal serotypes in elderly adults. *Clin Inf Dis* 2005;41:481-487.

Arthur Lawrence Reingold

187. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, Oyewo A, Talbot EA, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. *Clin Inf Dis* 2005;41:461-469.
188. Kyaw MH, Rose CE, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG for the Active Bacterial Core surveillance program of the Emerging Infections Program Network (includes Reingold AL). The influence of chronic illnesses on the incidence of invasive pneumococcal diseases in adults. *J Inf Dis* 2005;192:377-386.
189. Flannery B, Heffernan RT, Harrison LH, Ray SM, Reingold AL, Hadler J, Schaffner W, Lynfield R, Thomas AR, Jianmin Li DPE, Campsmith DDS, Whitney CG, Schuchat A. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. *Ann Int Med* 2006; 144:1-9.
190. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM Jr, Riley LW, Menzies D. Serial testing of health care workers for tuberculosis using interferon- γ assay. *Amer J Resp Crit Care Med* 2006;doi:10.1164/rccm.200604-4720C.
191. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant *Streptococcus pneumoniae*. *New Eng J Med* 2006;354:1455-1463.
192. Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL, Hadler JL, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. *JAMA* 2006;295:1668-1674.
193. Jones RM, Nicas M, Hubbard AE, Reingold AL. The infectious dose of *Coxiella burnetii* (Q Fever). *Appl Biosafety* 2006;11:32-41.
194. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman K, Vazquez M, Bennett NM, Reingold A, Thomas A, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. *Lancet* 2006; 368:1495-1502.
195. Hwang J, Bitarakwate E, Pai M, Reingold A, Rosenthal PJ, Dorsey G. Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for uncomplicated malaria: a systematic review. *Trop Med & Int Hlth* 2006;11:789-799.
196. Joshi R, Reingold AL, Menzies D, Pai M. Tuberculosis among health-care workers in low- and middle-income countries: A systematic review. *PLoS Med* 2006;3(12):e494. Doi:10.1371/journal.pmed.0030494
197. Pai NP, Lawrence J, Reingold AL, Tulskey JP. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. *Cochrane Database Syst Rev*. 2006;3:CD006148.
198. Schrag SJ, Hadler JL, Arnold KE, et al. Risk factors for invasive, early-onset *Escherichia coli* infections in the era of widespread intrapartum antibiotic use. *Pediatrics*. 2006;118(2):570-576.

Arthur Lawrence Reingold

199. Malamba SS, Mermin J, Reingold A, et al. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. *Am. J. Trop. Med. Hyg.* 2006;75(3):375-380.
200. Winkelstein W Jr, Reingold AL. Alex Langmuir and CDC. *Emerging Infect. Dis.* 2006;12(10):1619; author reply 1619.
201. Klevens RM, Morrison MA, Fridkin SK, et al. Community-associated methicillin-resistant *Staphylococcus aureus* and healthcare risk factors. *Emerging Infect. Dis.* 2006;12(12):1991-1993.
202. Aragón TJ, Vugia DJ, Shallow S, Samuel MC, Reingold A, Angulo FJ, Bradford WZ. Case-control study of shigellosis in San Francisco: The role of sexual transmission and HIV infection. *Clin Inf Dis* 2007;44:327-334.
203. Dogra S, Narang P, Mendiratta DK, Chaturvedi P, Reingold AL, Colford JM, Riley LW, Pai M. Comparison of a whole blood interferon- γ assay with tuberculin skin testing for the detection of tuberculosis infection in hospitalized children in rural India. *J Inf* 2007;54:267-276.
204. Nunes CLX, Andrade T, Galvão-Castro B, Bastos FI, Reingold A. Assessing risk behaviors and prevalence of sexually transmitted and blood-borne infections among female crack cocaine users in Salvador--Bahia, Brazil. *Braz J Infect Dis.* 2007;11(6):561-566.
205. Pai N, Peterson Tulsy J, Cohan D, Colford Jr JM, Reingold AL. Rapid point-of-care HIV testing in pregnant women: A systematic review and meta-analysis. *Trop Med and Int Hlth* 2007;12:1-12.
206. Madhivanan P, Krupp K, Chandrasekaran V, et al. The epidemiology of Herpes simplex virus type-2 infection among married women in Mysore, India. *Sex Transm Dis.* 2007;34(11):935-937.
207. Chainani-Wu N, Silverman Jr S, Reingold A, Bostrom A, McCulloch C, Lozada-Nur F, Weintraub J. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. *Phytomed* 2007;14:437-446.
208. Veras Maria Ameli SM, Enanoria WTA, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: A case control study. *BMC Inf Dis* 2007;7:119.
209. Krupp K, Madhivanan P, Karat C, Chandrasekaran V, Sarvode M, Klausner J, Reingold A. Novel recruitment strategies to increase participation of women in reproductive health research in India. *Glob Pub Hlth* 2007;4:395-403.
210. Lippman SA, Pulerwitz J, Chinaglia M, Hubbard A, Reingold AL, Diaz J. Mobility and its liminal context: Exploring sexual partnering among truck drivers crossing the Southern Brazilian border. *Soc Sci & Med* 2007;doi:10.1016.
211. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, Jackson D, Thomas A, Beall B, Lynfield R, Reingold AL, Farley MM, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. *J Inf Dis* 2007;196:1346-1354.

Arthur Lawrence Reingold

212. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold AL, Van Beneden C, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. *Clin Inf Dis* 2007;45:853-862.
213. Thigpen MC, Richards Jr CL, Lynfield R, Barrett NL, Harrison LH, Arnold KE, Reingold A, Bennett NM, et al. Invasive group A streptococcal infection in older adults in long-term care facilities and the community, United States, 1998-2003. *Emerg Inf Dis* 2007;13:1852-1859.
214. Malamba S, Hladik W, Reingold AL, Banage F, McFarland W, Rutherford G, Mimbe D, Nzaro E, Downing R, Mermin J. The effect of HIV on morbidity and mortality in children with severe malarial anaemia. *Malaria J* 2007;6:143.
215. Pant Pai N, Joshi R, Dogra S, Taksande B, Kalantri SP, Pai M, Narang P, Tulskey JP, Reingold AL. Evaluation of diagnostic accuracy, feasibility, and client preference for rapid oral fluid-based diagnosis of HIV infection in rural India. *PLoS One* 2007;2(4): e367.doi.10.1371/journal.pone.0000367.
216. Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, Lozada-Nur F, Weintraub J. Validation of visual analogue scale, numeric rating scale, change in symptoms scale and modified oral mucositis index for measurement of symptoms and signs of oral lichen planus. *Oral Surg Med Oral Pathol Oral Radiol Endod* 2008;105:51-58.
217. Koo D, Birkhead GS, Reingold AL. Competency-based epidemiologic training in public health practice. *Pub Hlth Rep* 2008 (Suppl 1);123:1-3.
218. Joshi R, Colford Jr JM, Reingold AL, Kalantri S. Nonmalarial acute undifferentiated fever in a rural hospital in Central India: Diagnostic uncertainty and overtreatment with anti-malarial agents. *Am J Trop Med Hyg* 2008;78:393-399.
219. Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, Gershman K, Reingold AL, Farley M, Harrison LH, et al. Population snapshot of emergent *Streptococcus pneumoniae* Serotype 19A in the United States, 2005. *J Inf Dis* 2008; 197:1016-1027.
220. Madhivanan P, Krupp K, Chandrasekaran V, Karat SC, Reingold AL, Klausner JD. Acceptability of male circumcision among mothers with male children in Mysore, India. *AIDS* 2008; 22:983-988.
221. Blumenshine P, Reingold A, Egerter S, Mockenhaupt R, Braveman P, Marks J. Pandemic influenza planning in the United States from a health disparities perspective. *Emerg Inf Dis* 2008; 14:5.
222. Madhivanan P, Krupp K, Chandrasekaran V, Karat C, Arun A, Cohen CR, Reingold AL, Klausner JD. Prevalence and correlates of bacterial vaginosis among young women of reproductive age in Mysore, India. *Ind J Med Microbiol* 2008; 26:132-137.
223. Pant Pai N, Joshi R, Moodie E EM, Taksande B, Kalantri SP, Pai M, Tulskey JP, Reingold AL. Profile of adults seeking voluntary HIV testing and counseling in rural Central India: Results from a hospital-based study. *AIDS Care* 2009;21:294-300.

Arthur Lawrence Reingold

224. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, Farley MM, Jorgensen JH, Lexau CA, Petit S, Reingold A, Schaffner W, Thomas A, Whitney CG, Harrison LH. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. *NEJM* 2009;360:244-256.
225. Gordon A, Ortega O, Kuan G, Reingold A, Saborio S, Balmaseda A, Harris E. Prevalence and seasonality of influenza-like illness in children, Nicaragua, 2005-2007. *Emerg Inf Dis* 2009;15:408-414.
226. Broyles LN, Van Beneden C, Beall B, Facklam R, Shewmaker PL, Malpiedi P, Daily P, Reingold A, Farley MM. Population-based study of invasive disease due to α -hemolytic streptococci of groups other than A and B. *Clin Inf Dis* 2009;48:706-712.
227. Madhivanan P, Krupp K, Hardin J, Karat C, Klausner JD, Reingold AL. Simple and inexpensive point-of-care tests improve diagnosis of vaginal infections in resource constrained settings. *Trop Med & Int Hlth* 2009;14:703-708.
228. Madhivanan P, Krupp K, Yashodha MN, Marlow L, Klausner JD, Reingold AL. Attitudes toward HPV vaccination among parents of adolescent girls in Mysore, India. *Vaccine* 2009;27:5203-5208.
229. Madhivanan P, Bartman MT, Pasutti L, et al. Prevalence of *Trichomonas vaginalis* infection among young reproductive age women in India: implications for treatment and prevention. *Sex Health*. 2009;6(4):339-344.
230. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, Rifampin, Ethambutol, and Pyrazinamide, pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. *Clin Inf Dis* 2009;48:1685-1694.
231. Carvalho M da G, Pimenta FC, Gertz RE Jr, Joshi HH, Trujillo AA, Keys LE, et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. *J. Clin. Microbiol.* 2009 Mar;47(3):554–9.
232. Gordon A, Videz E, Saborio S, et al. Performance of an influenza rapid test in children in a primary healthcare setting in Nicaragua. *PLoS ONE*. 2009;4(11):e7907.
233. Pai NP, Estes M, Moodie EEM, Reingold AL, Tulskey JP. The impact of antiretroviral therapy in a cohort of HIV infected patients going in and out of the San Francisco county jail. *PLoS ONE*. 2009;4(9):e7115.
234. Ahmad Y, Gertz RE Jr, Li Z, et al. Genetic relationships deduced from emm and multilocus sequence typing of invasive *Streptococcus dysgalactiae* subsp. *equisimilis* and *S. canis* recovered from isolates collected in the United States. *J. Clin. Microbiol.* 2009;47(7):2046-2054.
235. Eisenberg JNS, Aiello AE, Spicknall IH, Monto AS, Reingold A. Protecting the herd from H1N1. *Science*. 2009;326(5955):934; author reply 934.
236. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. *J Inf Dis* 2010;201:32-41.
237. Krupp K, Marlow LAV, Kielmann K, et al. Factors associated with intention-to-recommend human papillomavirus vaccination among physicians in Mysore, India. *J Adolesc Health*. 2010;46(4):379-384.

Arthur Lawrence Reingold

238. Lippman SA, Donini A, Díaz J, et al. Social-environmental factors and protective sexual behavior among sex workers: the Encontros intervention in Brazil. *Am J Public Health*. 2010;100 Suppl 1:S216-223.
239. Durrheim DN, Reingold A. Modifying the GRADE framework could benefit public health. *J Epidemiol Community Health*. 2010;64(5):387.
240. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. *Pediatrics*. 2010;126(1):e9-17.
241. Malamba S, Sandison T, Lule J, Reingold A, Walker J, Dorsey G, Mermin J. *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. *Am J Trop Med Hyg* 2010;82:766-771.
242. Dawood FS, Fiore A, Kamimoto L, Nowell M, Reingold A, Gershman K, Meek J, et al. Influenza-associated pneumonia in children hospitalized with laboratory-confirmed influenza, 2003-2008. *Ped Inf Dis* 2010;29:585-590.
243. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, et al. Health care-associated invasive MRSA infections, 2005-2008. *JAMA* 2010;304:641-648.
244. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. *Clin. Infect. Dis*. 2010;50(2):184-191.
245. Cohen AL, Harrison LH, Farley MM, et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. *AIDS*. 2010;24(14):2253-2262.
246. Dao CN, Kamimoto L, Nowell M, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. *J. Infect. Dis*. 2010;202(6):881-888.
247. Cochran LW, Black S, Klein NP, et al. Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. *Hum Vaccin*. 2010;6(9). Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20855940>. Accessed September 26, 2011.
248. Burton DC, Flannery B, Bennett NM, et al. Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. *Am J Public Health*. 2010;100(10):1904-1911.
249. Dawood FS, Fiore A, Kamimoto L, et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. *J. Pediatr*. 2010;157(5):808-814.
250. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold AL, et al. Bacterial meningitis in the United States, 1998-2007. *New Engl J Med* 2011; 364:2016-2025.
251. Pinho AA, Chinaglia M, Lippman SA, Reingold AL, Diaz RS, Sucupira MC, Page K, Diaz J. Prevalence and factors associated with HSV-2 and hepatitis B infections among truck drivers crossing the southern Brazilian border. *Sex Trans Infect* 2011; doi:10.1136/sextrans-2011-050186.

Arthur Lawrence Reingold

252. Veras MA de SM, Ribeiro MCA, Jamal LF, et al. The “AMA-Brazil” cooperative project: a nation-wide assessment of the clinical and epidemiological profile of AIDS-related deaths in Brazil in the antiretroviral treatment era. *Cad Saude Publica*. 2011;27 Suppl 1:S104-113.
253. Madhivanan P, Chen Y-H, Krupp K, et al. Incidence of Herpes simplex virus type 2 in young reproductive age women in Mysore, India. *Indian J Pathol Microbiol*. 2011;54(1):96-99.
254. Creanga AA, Kamimoto L, Newsome K, et al. Seasonal and 2009 pandemic influenza A (H1N1) virus infection during pregnancy: a population-based study of hospitalized cases. *Am. J. Obstet. Gynecol*. 2011;204(6 Suppl 1):S38-45.
255. Weston EJ, Pondo T, Lewis MM, et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. *Ped Inf Dis*. 2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21654548>. Accessed September 26, 2011.
256. Dawood FS, Kamimoto L, D’Mello TA, et al. Children with asthma hospitalized with seasonal or pandemic influenza, 2003-2009. *Pediatrics*. 2011;128(1):e27-32.
257. Rosen JB, Thomas AR, Lexau CA, et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. *Clin. Infect. Dis*. 2011;53(2):137-143.
258. Rathod SD, Krupp K, Klausner JD, et al. Bacterial vaginosis and risk for *Trichomonas vaginalis* infection: A longitudinal analysis. *Sex Transm Dis*. 2011;38(9):882-886.
259. Adamson PC, Krupp K, Freeman AH, Klausner JD, Reingold AL, Madhivanan P. Prevalence & correlates of primary infertility among young women in Mysore, India. *Indian J. Med. Res*. 2011 Oct;134:440–6.
260. Madhivanan P, Krupp K, Reingold A. Correlates of Intimate Partner Physical Violence Among Young Reproductive Age Women in Mysore, India. *Asia-Pacific journal of public health / Asia-Pacific Academic Consortium for Public Health [Internet]*. 2011 Dec 20 [cited 2012 Jun 18]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22186382>
261. MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, et al. Current epidemiology and trends in invasive *Haemophilus influenzae* disease--United States, 1989-2008. *Clin. Infect. Dis*. 2011 Dec;53(12):1230–6.
262. Doshi S, Kamimoto L, Finelli L, Perez A, Reingold A, Gershman K, et al. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. *J. Infect. Dis*. 2011 Dec 15;204(12):1848–56.
263. MacNeil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. *Pediatr. Infect. Dis. J*. 2011 Jun;30(6):451–5.
264. Lippman SA, Chinaglia M, Donini AA, Diaz J, Reingold A, Kerrigan DL. Findings from Encontros: a multilevel STI/HIV intervention to increase condom use, reduce STI, and change the social environment among sex workers in Brazil. *Sex Transm Dis*. 2012 Mar;39(3):209–16.

Arthur Lawrence Reingold

265. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. *J. Infect. Dis.* 2012 Jan 1;205(1):13–9.
266. Wise ME, Viray M, Sejvar JJ, Lewis P, Baughman AL, Connor W, et al. Guillain-Barre Syndrome during the 2009-2010 H1N1 influenza vaccination campaign: Population-based surveillance among 45 million Americans. *Am. J. Epidemiol.* 2012 Jun 1;175(11):1110–9.
267. Luckhaupt SE, Sweeney MH, Funk R, Calvert GM, Nowell M, D’Mello T, et al. Influenza-associated hospitalizations by industry, 2009-10 influenza season, United States. *Emerging Infect. Dis.* 2012 Apr;18(4):556–62.
268. Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, et al. Prevention of antibiotic-nonsusceptible *Streptococcus pneumoniae* with conjugate vaccines. *J. Infect. Dis.* 2012 Feb 1;205(3):401–11.
269. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. *Vaccine.* 2012 Jun 8;30(27):4067–72.
270. Reingold AL. Review: “Smallpox-The Death of a Disease: The Inside Story of Eradicating a Worldwide Killer” by D.A. Henderson. 2010; *Am J Epidemiol* 171:384-385.
271. Cohen AL, Taylor T Jr, Farley MM, Schaffner W, Leshner LJ, et al. An assessment of the screening method to evaluate vaccine effectiveness: The case of 7-valent pneumococcal conjugate vaccine in the United States. *PLoS One* 2012;7:341785. Doi:10.1371/journal.pone.0041785.
272. Henry JA, Reingold AL. Prehospital trauma systems reduce mortality in developing countries: A systematic review and meta-analysis. *Trauma Acute Care Surg* 2012;73:261-268.
273. Rathod SD, Klausner JD, Krupp K, Reingold AL, Madhivanan P. Epidemiologic features of vulvovaginal candidiasis among reproductive-age women in India. *Inf Dis Obst Gyn* 2012; Article ID 859071; doi:10.1155/2012/859071.
274. Duclos P, Durrheim DN, Reingold AL, Bhutta ZA, Vannice K, et al. Developing evidence-based immunization recommendations and GRADE*. *Vaccine* 2012;31:12-19.
275. Joshi R, Kalantri SP, Reingold AR, Colford JM. Changing landscape of acute encephalitis syndrome in India: A systematic review. *Nat Med J India* 2012;25:212-220.
276. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Venkat Narayan KM, Schaffner W, Thomas A, Lexau C, Bennett NM, Farley MM, Harrison LH, Reingold A, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. *Clin Inf Dis* 2013;56:e59-67.
277. Cox CM, D’Melio T, Perez A, Reingold A, Gershman K, et al. Increase in rates of hospitalization due to laboratory-confirmed influenza among children and adults during the 2009-2010 influenza pandemic. *J Inf Dis* 2012; 206:1350-1358.

Arthur Lawrence Reingold

278. Livorsi DJ, MacNeil JR, Cohn AC, Bareta J, Zansky S, Petit S, Gershman K, Harrison LH, Lynfield R, Reingold A, et al. Invasive *Haemophilus influenzae* in the United States, 1999-2008: Epidemiology and Outcomes. *J Inf Dis* 2012; 65:496-504.
279. * Keller AC, Ansell CK, Reingold AL, Bourrier M, Hunter MD, Burrowes S, MacPhail TM. Improving Pandemic Response: A Sensemaking Perspective on the Spring 2009 H1N1 Pandemic. *Risk, Hazards & Crisis in Public Policy*: Vol. 3: Iss. 2, Article 1; 2012. DOI: 10.1515/1944-4079.1101.
280. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. *Hepatology*; 2013;53:881-889.
281. Muhammed RD, Oza-Frank R, Zell E, Link-Gelles R, Venkat Narayan KM, Schaffner W, Thomas A, Lexau C, Bennett NM, Farley MM, Harrison LH, Reingold A, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. *Clin Inf Dis* 2013;56:e59-e67.
282. Fleming-Dutra KE, Taylor T, Link-Gelles R, Garg S, Jhung MA, Finelli L, Jain S, Shay D, Chaves SS, Baumbach J, Hancock EB, Beall B, Bennett N, Zansky S, Petit S, Yousey-Hindes K, Farley MM, Gershman K, Harrison LH, Ryan P, Lexau C, Lynfield R, Reingold A, et al. Effect of the 2009 influenza A(H1N1) pandemic on invasive pneumococcal pneumonia. *J Inf Dis* 2013;207:1135-1143.
283. Kamimoto L, Euler GL, Lu P-J, Reingold A, Hadler J, Gershman K, et al. Seasonal influenza morbidity estimates obtained from telephone surveys, 2007. *Am J Pub Hlth* 2013;103:755-763.
284. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR. . .H1N1 GBS Meta-Analysis Working Group (Reingold AL-member). Association between Guillain Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: A meta-analysis. *Lancet* 2013;381:1461-1468.
285. Ssekitoleko R, Kamya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: A systematic review and meta-analysis. *Future Virol* 2013;8:doi: 10.2217/fvl.13.71.
286. Joshi R, Mishra PK, Joshi D, Santhosh SR, Parida MM, Desikan P, Gangane N, Kalantri SP, Reingold A, Colford JM Jr. Clinical presentation, etiology, and survival in adult acute encephalitis syndrome in rural Central India. *Clin Neuro Neurosurg* 2013;115:1753-1761.
287. Dawood FS, Chaves SS, Perez A, Reingold A, Meek J, Farley MM, et al. Complications and associated bacterial coinfections among children hospitalized with seasonal or pandemic influenza, United States, 2003-2010. *J Inf Dis* 2013; Epub DOI: 10.1093/infdis/jit473.
288. Thompson MG, Sokolow LZ, Almendares O, Openo K, Farley MM, Meek J, Ray J, Daily Kirley P, Reingold A, et al. Effectiveness of nonadjuvanted monovalent influenza A (H1N1) pdm09 vaccines for preventing reverse transcription polymerase chain reaction-confirmed pandemic influenza hospitalizations: Case-control study of children and adults at 10 U.S. influenza surveillance network sites. *Clin Inf Dis* 2013;11:1587-1592.

Arthur Lawrence Reingold

289. Wiringa AE, Shutt KA, Marsh JW, Cohn AC, Messonnier NE, Zansky SM, Petit S, Farley MM, Gershman K, Lynfield R, Reingold A, et al. Geotemporal analysis of *Neisseria meningitidis* clones in the United States: 2000-2005. *PLoS One* 2013;8:e82048| doi:10.1371/journal.pone.0082048.
290. Woolf-King SE, Steinmaus CM, Reingold AL, Hahn JA. An update on alcohol use and risk of HIV infection in sub-Saharan Africa: Meta-analysis and future research directions. *IJADR*, 2013, 2(1), 99-110; doi: 10.7895/ijadr.v2i1.45.
291. Jhung MA, D'Mello T, Perez A, Aragon D, Bennett NM, Cooper T, Farley MM, Fowler B, Grube SM, Hancock EB, Lynfield R, Morin C, Reingold A, et al. Hospital-onset influenza hospitalizations – United States, 2010-2011. *Am J Inf Control* 2014; 42:7-11.
292. Ayieko J, Abuogi L, Simchowitz B, Bukusi EA, Smith AH, Reingold A. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. *BMC Inf Dis* 2014; 14:91; doi:10.1186/1471-2334-14-91.
293. Dharan NJ, Sokolow LZ, Cheng PY, Gargiullo P, Gershman K, Lynfield R, Morin C, Thomas A, Meek J, Farley MM, Arnold KE, Reingold A, et al. Child, household, and caregiver characteristics associated with hospitalization for influenza among children 6-59 months of age: an emerging infections program study. *Pediatr Infect Dis J*. 2014 Jun;33(6):e141-50. doi: 10.1097/INF.0000000000000283.PMID: 24642518.
294. Wortham JM, Zell ER, Pondo T, Harrison LH, Schaffner W, Lynfield R, Thomas A, Reingold A, et al. Racial disparities in invasive *Streptococcus pneumoniae* infections, 1998-2009. *Clin Infect Dis*. 2014 May;58(9):1250-7. doi: 10.1093/cid/ciu108. Epub 2014 Feb 27.PMID:24585565.
295. Madhivanan P, Raphael E, Rumphs A, Krupp K, Ravi K, Srinivas V, Arun A, Reingold AL, et al. Characterisation of culturable vaginal *Lactobacillus* species among women with and without bacterial vaginosis from the United States and India: A cross-sectional study. *J Med Microbiol*. 2014 Jul;63(Pt 7):931-5. doi: 10.1099/jmm.0.073080-0. Epub 2014 May 16.PMID :24836413.
296. Chaves SS, Perez A, Farley MM, Miller L, Schaffner W, Lindegren ML, Sharangpani R, Meek J, Yousey-Hindes K, Thomas A, Boulton R, Baumbach J, Hancock EB, Bandyopadhyay AS, Lynfield R, Morin C, Zansky SM, Reingold A, et al. The burden of influenza hospitalizations in infants from 2003 to 2012, United States. *Pediatr Infect Dis J*. 2014 Sep;33(9):912-9. doi:10.1097/INF.0000000000000321.PMID:24577042.
297. Blain A, MacNeil J, Wang X, Bennett N, Farley MM, Harrison LH, Lexau C, Miller L, Nichols M, Petit S, Reingold A, et al. Invasive *Haemophilus Influenzae* Disease in Adults ≥ 65 Years, United States, 2011. *Open Forum Infect Dis* (Summer 2014) 1 (2): first published online June 13, 2014. doi:10.1093/ofid/ofu044
298. Greenbaum A, Chaves S S, Perez A, Aragon D, Bandyopadhyay A, Bennett N, Fowler B, Hancock E, Lynfield R, McDonald-Hamm C, Reingold A, et al. Heavy alcohol use as a risk factor for severe outcomes among adults hospitalized with laboratory-confirmed influenza, 2005-2012. *Infection* (2014) 42:165-170. Doi 10.1007/s15010-013-0534-8.
299. Langley G, Schaffner W, Farley MM, Lynfield R, Bennett NM, Reingold A, et al. Twenty years of Active Bacterial Core surveillance. *Emerg Infect Dis*. 2015 Sept. <http://dx.doi.org/10.3201/eid2109.141333>.

Arthur Lawrence Reingold

300. Vugia DJ, Meek JI, Danila RN, Jones TF, Schaffner W, Baumbach J, Lathrop S, Farley MM, Tobin-D'Angelo M, Miller L, Harrison LH, Bennett NM, Cieslak PR, Cartter ML, Reingold A. Training in Infections Disease Epidemiology through the Emerging Infections Program Sites. *Emerg Infect Dis*. 2015 Sept. doi:<http://dx.doi.org/10.3201/eid2109.150443>.
301. MacNeil JR, Bennett N, Farley MM, Harrison LH, Lynfield R, Nichols M, Petit S, Reingold A, et al. Epidemiology of Infant Meningococcal Disease in the United States, 2006-2012. *Pediatrics* Volume 135, number 2, February 2015. doi:10.1542/peds.2014-2035.
302. Arriola CS, Anderson EJ, Baumbach J, Bennett N, Bohm S, Hill M, Lindegree ML, Lung K, Meek J, Mermel E, Miller L, Monroe ML, Morin C, Oni O, Reingold A, et al. Does Influenza Vaccination Modify Influenza Severity: Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States. *J. Infect Dis* March 2015. doi: 10.1093/infdis/jiv200.
303. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zankys SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. *Lancet Infect Dis* 2015; 15:301-09. [http://dx.doi.org/10.1016/S1473-3099\(14\)71081-3](http://dx.doi.org/10.1016/S1473-3099(14)71081-3).
304. Madhivanan P, Alleyn HN, Raphael E, Krupp K, Ravi K, Nebhrajani R, Arun A, Reingold A, et al. Identification of culturable vaginal *Lactobacillus* species among reproductive age women in Mysore, India. *Med Micro* (2015), 64. doi:10.1099/jmm.0.000070.
305. Brito AM, Kendall C, Kerr L, Salani Mota RM, Crosland Guimaraes MD, Dourado I, Pinho A, Schwartz Benzaken A, Brignol S, Reingold A. Factors Associated with Low Levels of HIV Testing among Men Who Have Sex with Men (MSM) in Brazil. *PLOS One* (2015). doi:10.1371/journal.pone.0130445.
306. Dorjee K, Dierberg K, Sadutshang TD, and Reingold A. First report of multi-drug resistant tuberculosis in a systemic lupus erythematosus patient. *BMC Res Notes* (2015) 8:337. doi 10.1186/s13104-015-1302-x.
307. Garg S, Jain S, Dawood F S, Jhung M, Perez A, D'Mello T, Reingold A, et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005-2008. *BMC Infectious Diseases* (2015) 15:369. Doi 10.1186/s12879-015-1004-y.
308. Shuster M, Eskola J, Duclos P, SAGE Working Group on Vaccine Hesitancy. Review of vaccine hesitancy: Rationale, remit, and methods. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.035>.
309. MacDonald N, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.36>.
310. Larson H, Jarrett C, Schulz W, Chaudhuri M, Zhou Y, Dube E, Schuster M, MacDonald N, Wilson R, SAGE Working Group on Vaccine Hesitancy. Measuring vaccine hesitancy: The development of a survey tool. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.37>.
311. Butler R, MacDonald N, SAGE Working Group on Vaccine Hesitancy. Diagnosing the determinants of vaccine hesitancy in specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.038>.

Arthur Lawrence Reingold

312. Jarrett C, Wilson R, O'Leary M, Eckersberger E, Larson H, SAGE Working Group on Vaccine Hesitancy. Strategies for addressing vaccine hesitancy—A systematic review. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.040>.
313. Dube E, Gagnon D, MacDonald N, SAGE Working Group on Vaccine History. Strategies intended to address vaccine hesitancy: Review of published reviews. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.0041>.
314. Nowak G, Gellin B, MacDonald N, Butler R, SAGE Working Group on Vaccine Hesitancy. Addressing vaccine hesitancy: The potential value of commercial and social marketing principles and practices. Nowak G, Gellin B, MacDonald N, Butler R, SAGE Working Group on Vaccine Hesitancy. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.039>.
315. Goldstein S, MacDonald N, Guirguis S, SAGE Working Group on Vaccine Hesitancy. Health Communication and vaccine hesitancy. Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.042>.
316. Eskoka J, Duclos P, Schuster M, MacDonald N, SAGE Working Group on Vaccine Hesitancy. How to deal with vaccine hesitancy? Elsevier Ltd. 2015. <http://dx.doi.org/10.1016/j.vaccine.2015.04.043>.
317. Rathod SD, Li T, Klausner JD, Hubbard A, Reingold AL, and Madhivanan P, Logic regression-derived algorithms for syndromic management of vaginal infections. Medical Informatics and Decision Making. 2015. 15:106. DOI 10.1186/s12911-015-0228-5.
318. Vugia DJ, Meek JI, Danila RN, Jones TF, Schaffner W, Baumbach J, Lathrop S, Farley MM, Tobin-D'Angelo M, Miller L, Harrison LH, Bennett NM, Cieslak PR, Cartter ML, Reingold AL. Training in Infectious Disease Epidemiology through the Emerging Infections Program Sites. Emerging Infectious Diseases. Vol. 21, No. 9; September 2015.
319. Smith EM, Khan MA, Reingold AL, Watt JP. Group B streptococcus infections of soft tissue and bone in California adults, 1995-2012. Epidemiol. Infect. (2015), 143, 3343-3350. Doi:10.1017/S0950268815000606.
320. Pekka N, Reingold A. Preventing pneumococcal infections in older adults. The Lancet, Vol 3 November 2015. [http://dx.doi.org/10.1016/52213-2600\(15\)00365-3](http://dx.doi.org/10.1016/52213-2600(15)00365-3).
321. Tomczyk S, Lynfield R, Schaffner W, Reingold A, et al. Prevention of Antibiotic-Nonsusceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clin Infect Dis 2016;62(9):1119-25. DOI: 10.1093/cid/ciw067.
322. Cardoso CS, Sabino EC, Oliveira CdL, de Oliveira LC, Ferreira AM, Cunha-Neto E, Bierrenback AL, Ferreira JE, Haikal DS, Reingold AL, et al. Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. BMJ Open 2016;6:e011181. doi:10.1136/bmjopen-2016-011181.
323. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Haltzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. The Lancet, Vol 4 May 2016. [http://dx.doi.org/10.1016/52213-2600\(16\)00052-7](http://dx.doi.org/10.1016/52213-2600(16)00052-7).

324. Bramley AM, Chaves SS, Dawood FS, Doshi S, Reingold A, et al. Utility of keywords from chest radiograph reports for pneumonia surveillance among hospitalized patients with influenza: The CDC Influenza Hospitalization Surveillance Network, 2008-2009. *Public Health Reports*. May/Jun 2016, Vol. 131 Issue 3, p483-490.
325. Blain AE, Sema M, Wu H, MacNeail JR, Harrison LH, Farley MM, Lynfield R, Miller L, Nichols M, Petit S, Reingold A, et al. Penicillin use in meningococcal disease management: Active Bacterial Core Surveillance Sites, 2009. *Open Forum Infectious Diseases*. 11 July 2016. doi: 10.1093/ofid/ofw152.
326. Link-Gelles R, Westreich D, Aiello AE, Shang N, Weber DJ, Holtzman C, Scherzinger K, Reingold A, et al. Bias with respect to socioeconomic status: a closer look at zip code matching in a pneumococcal vaccine effectiveness study. 8 August 2016. Elsevier. <http://dx.doi.org/10.1016/j.ssmph.2016.08.005>.
327. Higgins JPT, Soares-Weiser K, Lopez JA, Kakourou A, Chaplin K, Martin NK, Sterne JAC, Reingold A. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. *BMJ*. 2016;355:i5170. doi:10.1136/bmj.i5170.
328. Andreuccetti G, Leyton V, Lemos NP, Miziara ID, Ye Y, Takitane J, Munoz DR, Reingold AL, et al. Alcohol use among fatally injured victims in São Paulo, Brazil: bridging the gap between research and health services in developing countries., 2016 Nov 6. doi: 10.1111/add.13688. [Epub ahead of print]
329. Harris CM, Wu HM, Li J, Hall HI, Lee A, Zell E, Harrison LH, Petit S, Farley MM, Lynfield R, Miller L, Nichols M, Reingold A, et al. Meningococcal disease in patients with human immunodeficiency virus infection: a review of cases reported through active surveillance in the United States, 2000-2008. *Open Forum Infect Dis*. 2016 Dec 20;3(4):ofw226. doi: 10.1093/ofid/ofw226.
330. Schrag SJ, Farley MM, Petit S, Reingold A, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. *Pediatrics*. 2016 Dec; 138(6). pii: e20162013.
331. Metcalf BJ, Chochua S, Gertz RE, Li Z, et al. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States, *Clinical Microbiology and Infection*, Volume 22, Issue 12, 2016, Pages 1002.e1-1002.e8, <https://doi.org/10.1016/j.cmi.2016.08.001>.
332. Wesson P, Reingold A, McFarland W. Theoretical and empirical comparisons of methods to estimate the size of hard-to-reach populations: a systematic review. *AIDS Behav*. 2017 Jan 11. doi: 10.1007/s10461-017-1678-9. [Epub ahead of print] Review.
333. Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold AL, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. *Pediatrics*. Volume 139, No. 2; February 2017.
334. Belongia EA, Karron RA, Reingold A, et al. The Advisory Committee on Immunization Practices recommendations regarding the use of live influenza vaccine: a rejoinder. *Vaccine* (2017), <http://dx.doi.org/10.1016/j.vaccine.2017.06.017>.

Arthur Lawrence Reingold

335. Carmen SA, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM, Bennett N, Reingold A, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clin Infect Dis* 2017 cix468. doi: 10.1093/cid/cix468.
336. Link-Gelles R, Westreich D, Aiello AE, Shang N, Weber DJ, Rosen JB, Motala T, Mascola L, Eason J, Scherzinger K, Holtzman C, Reingold AL, et al. Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA. *BMJ Open* 2017; 7:e017715. doi:10.1136/bmjopen-2017-017715.
337. Metcalf BJ, Chochua S, Girtz Jr. RE, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive *Streptococcus agalactiae* recovered in the USA, *Clinical Microbiology and Infection*, Volume 23, Issue 8, 18 Feb 2017, Pages 574.e7-574.e14, <https://doi.org/10.1016/j.cmi.2017.02.021>
338. Arriola C, Garg S, Anderson E, Ryan PA, George A, Zansky SM, Bennett N, Reingold A, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. *Clin Infect Dis* May 2017;00(00):1-9. Doi:10.1093/cid/cix468.
339. Wong KK, Burdette E, Mahon B, et al. Recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of cholera vaccine. *MMWR* 12 May 2017, 66(18):482-485). DOI: 10.15585/mmwr.mm6618a6.
340. Wesson P, Lechtenberg R, Reingold, A, et al. Evaluating the completeness of HIV surveillance using capture-recapture models, Alameda County, California. *AIDS Behav* 21 August 2017. Doi: 10.1007/s10461-017-1883-6.
341. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. *Vaccine* 36 (2018); A1-A34; <https://doi.org/10.1016/j.vaccine.2017.09.026>
342. Orenstein WA, Cairns L., Hinman .A, Nkowane B., J-M., Olive, Reingold A.L. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: background and summary. *Vaccine* 36 (2018) A35-A42: <https://doi.org/10.1016/j.vaccine.2017.10.065>.
343. Schille S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. (ACIP) *MMWR*:12 January 2018: 67(1);1-31. https://www.cdc.gov/mmwr/volumes/67/rr/rr/rr6701a1.htm?s_cid=rr6701a1_w
344. Gordon A, Reingold A. The burden of influenza: a complex problem. *Current Epidemiology Reports*: 05 February 2018. <https://doi.org/10.1007/s40471-018-0136-1>.
345. Liang JL, Tiwari T, Moro P, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommendations and Reports*. 27 April 2018;67(2):1-44. doi:10.15585/mmwr.rr6702a1.

346. G. Andreuccetti, C.J. Cherpitel, H.B. Carvalho, V. Leyton, I.D. Miziara, D.R. Munoz, A.L. Reingold, et al. Alcohol in combination with illicit drugs among fatal injuries in Sao Paulo, Brazil: An epidemiological study on the association between acute substance use and injury, *Injury*, Volume 49, Issue 12, 2018, Pages 2186-2192, ISSN 0020-1383, <https://doi.org/10.1016/j.injury.2018.09.035>. (<http://www.sciencedirect.com/science/article/pii/S0020138318305400>)
347. Soeters HM, Blain A, Pondo T, Doman B, Farley MM, Harrison LH, Lynfield R, Miller L, Petit S, Reingold A, et al. Current epidemiology and trends in invasive *Haemophilus influenzae* disease—United States, 2009–2015, *Clin Infect Dis*, Volume 67, Issue 6, 15 September 2018, Pages 881–889, <https://doi.org/10.1093/cid/ciy187>
348. O'Brien KS, Emerson P, Hooper PJ, Reingold AL, et al. Antimicrobial resistance following mass azithromycin distribution for trachoma: a systematic review. *Lancet Infect. Dis* 2018. October 3, 2018. [http://dx.doi.org/10.1016/S1473-3099\(18\)30444-4](http://dx.doi.org/10.1016/S1473-3099(18)30444-4)
349. Mendes Lobão W, Duarte FG, Burns JD, et al. Low coverage of HPV vaccination in the national immunization programme in Brazil: Parental vaccine refusal or barriers in health-service based vaccine delivery. *PLoS One*. 2018;13(11):e0206726. Published 2018 Nov 12. doi:10.1371/journal.pone.0206726
350. Duarte FG, da Silva Moreir S, da Conceicao C Almeida M, de Souza Teles CA, Andrade CS, Reingold A, et al. Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela. *BMJ Open*. 2019;9:e023401. Doi:10.1136/bmjopen-2018-023401
351. Lewnard JA, Reingold AL, Emerging challenges and opportunities in infectious disease epidemiology, *Am J Epi*. Volume 188, Issue 5, May 2019, Pages 873–882. <https://doi.org/10.1093/aje/kwy264>
352. Schaffner W, Nichol KL, Reingold AL, Preventing hepatitis in US adults through vaccination. *Infect Dis in Clini Pract*: November 2018, Volume 26, Issue 6 p 304-312. doi: 10.1097/IPC.0000000000000685.
353. Cardoso CS, Ribeiro ALP, Oliveira CDL, Oliveira LC, Ferreira AM, Bierrenbach AL, Silva JLP, Colosimo EA, Ferreira JE, Lee TH, Busch MP, Reingold AL, et al. Beneficial effects of benznidazole in chagas disease: NIH SaMi-Trop cohort study. 2018 *PLoS Neglected Tropical Diseases*, 12(11), p.e0006814.
354. Dorjee K, Choden T, Baxi SM, Steinmaus C, and Reingold AL, 2018. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analysis of results from 17 epidemiologic studies. *Int J Antimicrobial Agents*, 52(5), pp.541-553. <https://doi.org/10.1016/j.ijantimicag.2018.07.010>.
355. Ahmed SS, Pondo T, Xing W, McGee L, Farley M, Schaffner W, Thomas A, Reingold A, et al. 2019. Early impact of 13-valent pneumococcal conjugate vaccine use on invasive pneumococcal disease among adults with and without underlying medical conditions—United States. *Clin Infect Dis*. CID 2019:XX(XX):1-9. doi:10.1093/cid/ciz739.
356. Dorjee K., Baxi S.M., Reingold A. et al. 2017. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. *BMC Infect Dis* 17, 708 <https://doi-org.libproxy.berkeley.edu/10.1186/s12879-017-2808-8>

Arthur Lawrence Reingold

357. O'Brien KS, Byanju R, Kandel RP The Village-Integrated Eye Worker Trial Group, et al Village-Integrated Eye Worker trial (VIEW): rationale and design of a cluster-randomised trial to prevent corneal ulcers in resource-limited settings. *BMJ Open* 2018; 8:e021556. doi: 10.1136/bmjopen-2018-021556
358. Lee G, Carr W Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices. *MMWR Morb Mortal Wkly Rep* 2018;67:1271–1272. DOI: <http://dx.doi.org/10.15585/mmwr.mm6745a4>
359. Arriola CS, Kim L, Langley G, Anderson EJ, Openo K, Martin AM, Lynfield R, Bye E, Como-Sabetti K, Reingold A, Chai S, Daily P, Thomas A, Crawford C, Reed C, Garg S, Chaves SS, Estimated burden of community-onset respiratory syncytial virus–associated hospitalizations among children aged <2 years in the United States, 2014–15, *J Pediatric Infect Dis Soc.* 2019. piz087, <https://doi-org.libproxy.berkeley.edu/10.1093/jpids/piz087>
360. Martinez L, Cords O, Horsburgh CR, Andrews J, Pediatric TB contact studies consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. *Lancet* 2020; 395(10228): pp. 973-984. doi: [https://doi.org/10.1016/S0140-6736\(20\)30166-5](https://doi.org/10.1016/S0140-6736(20)30166-5)
361. Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington. *BMJ* 2020; 369:m1923 doi:10.1136/bmj.m1923
362. Kim L, Whitaker M, O'Halloran A, Kambhampati A, Chai S, Reingold A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 – COVID-NET, 14 States, March 1- July 25, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(32):1081-1088. Aug 2020. doi:10.15585/mmwr.mm6932e3
363. Benjamin-Chung J, Arnold BF, Kennedy CJ, et al. Evaluation of a city-wide school-located influenza vaccination program in Oakland, California with respect to vaccination coverage, school absences, and laboratory-confirmed influenza: a matched cohort study. *PLOS Med* 2020; In Press.
364. Wu S, Mertens A, Crider Y, Nguyen A, Pokpongkiet N, Djajadi S, et al. Substantial underestimation of SARS-CoV-2 infection in the United States. *Nature Communications*, 2020.In Press.